1
|
Shepard BD, Chau J, Kurtz R, Rosenberg AZ, Sarder P, Border SP, Ginley B, Rodriguez O, Albanese C, Knoer G, Greene A, De Souza AMA, Ranjit S, Levi M, Ecelbarger CM. Nascent shifts in renal cellular metabolism, structure, and function due to chronic empagliflozin in prediabetic mice. Am J Physiol Cell Physiol 2024; 326:C1272-C1290. [PMID: 38602847 DOI: 10.1152/ajpcell.00446.2023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2023] [Revised: 02/21/2024] [Accepted: 02/21/2024] [Indexed: 04/13/2024]
Abstract
Sodium-glucose cotransporter, type 2 inhibitors (SGLT2i) are emerging as the gold standard for treatment of type 2 diabetes (T2D) with renal protective benefits independent of glucose lowering. We took a high-level approach to evaluate the effects of the SGLT2i, empagliflozin (EMPA) on renal metabolism and function in a prediabetic model of metabolic syndrome. Male and female 12-wk-old TallyHo (TH) mice, and their closest genetic lean strain (Swiss-Webster, SW) were treated with a high-milk-fat diet (HMFD) plus/minus EMPA (@0.01%) for 12-wk. Kidney weights and glomerular filtration rate were slightly increased by EMPA in the TH mice. Glomerular feature analysis by unsupervised clustering revealed sexually dimorphic clustering, and one unique cluster relating to EMPA. Periodic acid Schiff (PAS) positive areas, reflecting basement membranes and mesangium were slightly reduced by EMPA. Phasor-fluorescent life-time imaging (FLIM) of free-to-protein bound NADH in cortex showed a marginally greater reliance on oxidative phosphorylation with EMPA. Overall, net urine sodium, glucose, and albumin were slightly increased by EMPA. In TH, EMPA reduced the sodium phosphate cotransporter, type 2 (NaPi-2), but increased sodium hydrogen exchanger, type 3 (NHE3). These changes were absent or blunted in SW. EMPA led to changes in urine exosomal microRNA profile including, in females, enhanced levels of miRs 27a-3p, 190a-5p, and 196b-5p. Network analysis revealed "cancer pathways" and "FOXO signaling" as the major regulated pathways. Overall, EMPA treatment to prediabetic mice with limited renal disease resulted in modifications in renal metabolism, structure, and transport, which may preclude and underlie protection against kidney disease with developing T2D.NEW & NOTEWORTHY Renal protection afforded by sodium glucose transporter, type 2 inhibitors (SGLT2i), e.g., empagliflozin (EMPA) involves complex intertwined mechanisms. Using a novel mouse model of obesity with insulin resistance, the TallyHo/Jng (TH) mouse on a high-milk-fat diet (HMFD), we found subtle changes in metabolism including altered regulation of sodium transporters that line the renal tubule. New potential epigenetic determinants of metabolic changes relating to FOXO and cancer signaling pathways were elucidated from an altered urine exosomal microRNA signature.
Collapse
Affiliation(s)
- Blythe D Shepard
- Department of Human Science, Georgetown University, Washington, District of Columbia, United States
| | - Jennifer Chau
- Department of Medicine,Georgetown University, Washington, District of Columbia, United States
| | - Ryan Kurtz
- Department of Human Science, Georgetown University, Washington, District of Columbia, United States
| | - Avi Z Rosenberg
- Department of Pathology, Johns Hopkins University, Baltimore, Maryland, United States
| | - Pinaki Sarder
- J Crayton Pruitt Department of Biomedical Engineering, University of Florida, Gainesville, Florida, United States
| | - Samuel P Border
- J Crayton Pruitt Department of Biomedical Engineering, University of Florida, Gainesville, Florida, United States
| | - Brandon Ginley
- Department of Pathology, Johns Hopkins University, Baltimore, Maryland, United States
- Department of Computational Cell Biology, Anatomy, and Pathology, State University of New York at Buffalo, Buffalo, New York, United States
| | - Olga Rodriguez
- Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia, United States
- Center for Translational Imaging, Georgetown University, Washington, District of Columbia, United States
| | - Chris Albanese
- Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia, United States
- Center for Translational Imaging, Georgetown University, Washington, District of Columbia, United States
- Department of Radiology, Georgetown University, Washington, District of Columbia, United States
| | - Grace Knoer
- Center for Translational Imaging, Georgetown University, Washington, District of Columbia, United States
| | - Aarenee Greene
- Department of Medicine,Georgetown University, Washington, District of Columbia, United States
| | - Aline M A De Souza
- Department of Medicine,Georgetown University, Washington, District of Columbia, United States
| | - Suman Ranjit
- Department of Biochemistry and Molecular & Cellular Biology, Georgetown University, Washington, District of Columbia, United States
- Microscopy & Imaging Shared Resources, Georgetown University, Washington, District of Columbia, United States
| | - Moshe Levi
- Department of Biochemistry and Molecular & Cellular Biology, Georgetown University, Washington, District of Columbia, United States
| | - Carolyn M Ecelbarger
- Department of Medicine,Georgetown University, Washington, District of Columbia, United States
| |
Collapse
|
2
|
Harvey-Jones E, Raghunandan M, Robbez-Masson L, Magraner-Pardo L, Alaguthurai T, Yablonovitch A, Yen J, Xiao H, Brough R, Frankum J, Song F, Yeung J, Savy T, Gulati A, Alexander J, Kemp H, Starling C, Konde A, Marlow R, Cheang M, Proszek P, Hubank M, Cai M, Trendell J, Lu R, Liccardo R, Ravindran N, Llop-Guevara A, Rodriguez O, Balmana J, Lukashchuk N, Dorschner M, Drusbosky L, Roxanis I, Serra V, Haider S, Pettitt SJ, Lord CJ, Tutt ANJ. Longitudinal profiling identifies co-occurring BRCA1/2 reversions, TP53BP1, RIF1 and PAXIP1 mutations in PARP inhibitor-resistant advanced breast cancer. Ann Oncol 2024; 35:364-380. [PMID: 38244928 DOI: 10.1016/j.annonc.2024.01.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2024] Open
Abstract
BACKGROUND Resistance to therapies that target homologous recombination deficiency (HRD) in breast cancer limits their overall effectiveness. Multiple, preclinically validated, mechanisms of resistance have been proposed, but their existence and relative frequency in clinical disease are unclear, as is how to target resistance. PATIENTS AND METHODS Longitudinal mutation and methylation profiling of circulating tumour (ct)DNA was carried out in 47 patients with metastatic BRCA1-, BRCA2- or PALB2-mutant breast cancer treated with HRD-targeted therapy who developed progressive disease-18 patients had primary resistance and 29 exhibited response followed by resistance. ctDNA isolated at multiple time points in the patient treatment course (before, on-treatment and at progression) was sequenced using a novel >750-gene intron/exon targeted sequencing panel. Where available, matched tumour biopsies were whole exome and RNA sequenced and also used to assess nuclear RAD51. RESULTS BRCA1/2 reversion mutations were present in 60% of patients and were the most prevalent form of resistance. In 10 cases, reversions were detected in ctDNA before clinical progression. Two new reversion-based mechanisms were identified: (i) intragenic BRCA1/2 deletions with intronic breakpoints; and (ii) intragenic BRCA1/2 secondary mutations that formed novel splice acceptor sites, the latter being confirmed by in vitro minigene reporter assays. When seen before commencing subsequent treatment, reversions were associated with significantly shorter time to progression. Tumours with reversions retained HRD mutational signatures but had functional homologous recombination based on RAD51 status. Although less frequent than reversions, nonreversion mechanisms [loss-of-function (LoF) mutations in TP53BP1, RIF1 or PAXIP1] were evident in patients with acquired resistance and occasionally coexisted with reversions, challenging the notion that singular resistance mechanisms emerge in each patient. CONCLUSIONS These observations map the prevalence of candidate drivers of resistance across time in a clinical setting, information with implications for clinical management and trial design in HRD breast cancers.
Collapse
Affiliation(s)
- E Harvey-Jones
- The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK; The Breast Cancer Now Research Unit, Guy's Hospital Cancer Centre, King's College London, UK; The City of London Cancer Research UK Centre at King's College London, UK
| | - M Raghunandan
- The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK
| | - L Robbez-Masson
- The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK
| | - L Magraner-Pardo
- The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK
| | - T Alaguthurai
- The Breast Cancer Now Research Unit, Guy's Hospital Cancer Centre, King's College London, UK
| | | | - J Yen
- Guardant Health Inc., Redwood City, USA
| | - H Xiao
- The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK
| | - R Brough
- The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK
| | - J Frankum
- The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK
| | - F Song
- The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK
| | - J Yeung
- The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK
| | - T Savy
- The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK
| | - A Gulati
- The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK
| | - J Alexander
- The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK
| | - H Kemp
- The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK
| | - C Starling
- The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK
| | - A Konde
- The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK
| | - R Marlow
- The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK
| | - M Cheang
- Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, UK
| | - P Proszek
- Clinical Genomics, The Royal Marsden Hospital, London, UK
| | - M Hubank
- Clinical Genomics, The Royal Marsden Hospital, London, UK
| | - M Cai
- Guardant Health Inc., Redwood City, USA
| | - J Trendell
- The Breast Cancer Now Research Unit, Guy's Hospital Cancer Centre, King's College London, UK
| | - R Lu
- The Breast Cancer Now Research Unit, Guy's Hospital Cancer Centre, King's College London, UK
| | - R Liccardo
- The Breast Cancer Now Research Unit, Guy's Hospital Cancer Centre, King's College London, UK
| | - N Ravindran
- The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK
| | | | - O Rodriguez
- Vall d'Hebron Institute of Oncology, Barcelona, Spain
| | - J Balmana
- Vall d'Hebron Institute of Oncology, Barcelona, Spain
| | | | | | | | - I Roxanis
- The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK
| | - V Serra
- Vall d'Hebron Institute of Oncology, Barcelona, Spain
| | - S Haider
- The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK
| | - S J Pettitt
- The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.
| | - C J Lord
- The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.
| | - A N J Tutt
- The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK; The Breast Cancer Now Research Unit, Guy's Hospital Cancer Centre, King's College London, UK; The City of London Cancer Research UK Centre at King's College London, UK.
| |
Collapse
|
3
|
Naeem A, Knoer G, Avantaggiati ML, Rodriguez O, Albanese C. Provocative non-canonical roles of p53 and AKT signaling: A role for Thymosin β4 in medulloblastoma. Int Immunopharmacol 2023; 116:109785. [PMID: 36720193 DOI: 10.1016/j.intimp.2023.109785] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2022] [Revised: 01/15/2023] [Accepted: 01/16/2023] [Indexed: 01/30/2023]
Abstract
The PI3K/AKT and p53 pathways are key regulators of cancer cell survival and death, respectively. Contrary to their generally accepted roles, several lines of evidence, including ours in medulloblastoma, the most common childhood brain cancer, highlight non-canonical functions for both proteins and show a complex context-dependent dynamic behavior in determining cell fate. Interestingly, p53-mediated cell survival and AKT-mediated cell death can dominate in certain conditions, and these interchangeable physiological functions may potentially be manipulated for better clinical outcomes. This review article presents studies in which p53 and AKT behave contrary to their well-established functions. We discuss the factors and circumstances that may be involved in mediating these changes and the implications of these unique roles of p53 and AKT in devising therapeutic strategies. Lastly, based on our recent finding of Thymosin beta 4-mediated chemosensitivity via an AKT-p53 interaction in medulloblastoma cells, we also discuss the possible implications of Thymosin beta-4 in enhancing drug sensitivity in this deadly childhood disease.
Collapse
Affiliation(s)
- Aisha Naeem
- Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20057, USA; Health Research Governance Department, Ministry of Public Health, Qatar.
| | - Grace Knoer
- Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20057, USA
| | - Maria Laura Avantaggiati
- Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20057, USA
| | - Olga Rodriguez
- Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20057, USA; Center for Translational Imaging, Georgetown University Medical Center, Washington, DC 20057, USA
| | - Chris Albanese
- Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20057, USA; Department of Radiology, Georgetown University Medical Center, Washington, DC 20057, USA; Center for Translational Imaging, Georgetown University Medical Center, Washington, DC 20057, USA.
| |
Collapse
|
4
|
Rosko LM, Gentile T, Smith VN, Manavi Z, Melchor GS, Hu J, Shults NV, Albanese C, Lee Y, Rodriguez O, Huang JK. Cerebral Creatine Deficiency Affects the Timing of Oligodendrocyte Myelination. J Neurosci 2023; 43:1143-1153. [PMID: 36732069 PMCID: PMC9962777 DOI: 10.1523/jneurosci.2120-21.2022] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2021] [Revised: 10/10/2022] [Accepted: 11/10/2022] [Indexed: 02/04/2023] Open
Abstract
Cerebral creatine deficiency syndrome (CCDS) is an inborn error of metabolism characterized by intellectual delays, seizures, and autistic-like behavior. However, the role of endogenously synthesized creatine on CNS development and function remains poorly understood. Here, magnetic resonance spectroscopy of adult mouse brains from both sexes revealed creatine synthesis is dependent on the expression of the enzyme, guanidinoacetate methyltransferase (GAMT). To identify Gamt-expressed cells, and how Gamt affects postnatal CNS development, we generated a mouse line by knocking-in a GFP, which is expressed on excision of Gamt We found that Gamt is expressed in mature oligodendrocytes during active myelination in the developing postnatal CNS. Homozygous deletion of Gamt resulted in significantly reduced mature oligodendrocytes and delayed myelination in the corpus callosum. Moreover, the absence of endogenous creatine resulted in altered AMPK signaling in the brain, reduced brain creatine kinase expression in cortical neurons, and signs of axonal damage. Experimental demyelination in mice after tamoxifen-induced conditional deletion of Gamt in oligodendrocyte lineage cells resulted in delayed maturation of oligodendrocytes and myelin coverage in lesions. Moreover, creatine and cyclocreatine supplementation can enhance remyelination after demyelination. Our results suggest endogenously synthesized creatine controls the bioenergetic demand required for the timely maturation of oligodendrocytes during postnatal CNS development, and that delayed myelination and altered CNS energetics through the disruption of creatine synthesis might contribute to conditions, such as CCDS.SIGNIFICANCE STATEMENT Cerebral creatine deficiency syndrome is a rare disease of inborn errors in metabolism, which is characterized by intellectual delays, seizures, and autism-like behavior. We found that oligodendrocytes are the main source of endogenously synthesized creatine in the adult CNS, and the loss of endogenous creatine synthesis led to delayed myelination. Our study suggests impaired cerebral creatine synthesis affects the timing of myelination and may impact brain bioenergetics.
Collapse
Affiliation(s)
- Lauren M Rosko
- Department of Biology, Georgetown University, Washington, DC 20057
- Interdisciplinary Program in Neuroscience, Georgetown University, Washington, DC 20057
| | - Tyler Gentile
- Department of Biology, Georgetown University, Washington, DC 20057
| | - Victoria N Smith
- Department of Biology, Georgetown University, Washington, DC 20057
| | - Zeeba Manavi
- Department of Biology, Georgetown University, Washington, DC 20057
| | - George S Melchor
- Department of Biology, Georgetown University, Washington, DC 20057
- Interdisciplinary Program in Neuroscience, Georgetown University, Washington, DC 20057
| | - Jingwen Hu
- Department of Biology, Georgetown University, Washington, DC 20057
| | | | - Chris Albanese
- Department of Oncology, Georgetown University Medical Center, Washington, DC 20057
| | - Yichien Lee
- Department of Oncology, Georgetown University Medical Center, Washington, DC 20057
| | - Olga Rodriguez
- Department of Oncology, Georgetown University Medical Center, Washington, DC 20057
| | - Jeffrey K Huang
- Department of Biology, Georgetown University, Washington, DC 20057
- Interdisciplinary Program in Neuroscience, Georgetown University, Washington, DC 20057
| |
Collapse
|
5
|
Adnani M, Hong SH, Galli S, Mahajan A, Abualsaud N, Caprio L, Tilan JU, Rodriguez O, Wang H, Albanese C, Cavalli LR, Kitlinska J. Abstract PR018: Neuropeptide Y as a metastatic factor. Cancer Res 2023. [DOI: 10.1158/1538-7445.metastasis22-pr018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
Abstract
Although neuropeptide Y (NPY) is known mainly as a sympathetic neurotransmitter, growing evidence indicates its role in tumor biology. Previous studies from our laboratory and other groups suggested associations of high expression of NPY and its Y5 receptor (Y5R) with invasive and metastatic phenotypes of various tumor types; yet the direct evidence for the metastatic activity was lacking. Our recent work began to fill this gap. Using Ewing sarcoma (ES) as a model of NPY-rich tumor, we identified the NPY/Y5R axis as a crucial pathway responsible for hypoxia-induced ES bone metastasis. This osseous dissemination was driven by hypoxia-dependent over-activation of the NPY/Y5R/RhoA pathway, which led to cytokinesis defects and formation of the aneuploid ES cell population with high propensity to bone metastasis. Here, we sought to determine the impact of the Y5R signaling on overall, hypoxia-independent metastatic capabilities of ES cells. To this end, a doxycycline-inducible CRIPSR/Cas9 system was used to knockout Y5R in ES orthotopic xenografts and test its impact on metastasis and cell migration assessed by a transwell assay. The frequency of the NPY5R gene modifications was determined by sequencing and confirmed by immunohistochemistry. FISH was used to identify NPY5R gene gains in ES xenografts. RhoA activity was measured by immunocytochemistry and pull-down assay. As expected, ES/Y5R-sgRNA primary tumors in doxycycline-treated mice consisted of a heterogeneous ES cell population with variable Y5R levels. In contrast, metastases developing from these xenografts were primarily initiated by ES clones with an intact NPY5R gene. The frequency of NPY5R gene modifications in metastases from the doxycycline-treated group was markedly reduced, as compared to the primary tumors. No metastases arising from ES clones lacking intact NPY5R gene were detected. Similarly, metastasis from wild type ES xenografts was associated with a selection of clones with the NPY5R gene gain that was present in a small percent of the parental cells. Subsequent in vitro assays implicated Y5R-dependent ES cell motility driven by the activation of a key cytoskeleton regulator, RhoA, as the mechanism underlying the metastatic effects of NPY. The above results, along with our previously published data, provide direct evidence for the crucial role of the NPY/Y5R axis in metastasis. We have shown that under basal conditions the NPY/Y5R/RhoA axis promotes tumor cell motility and overall cancer cell dissemination, while over-activation of this pathway under hypoxic conditions leads to genomic instability and bone metastasis. While our study focused on ES due to its high endogenous expression of NPY and its receptors, our findings may be relevant to other malignancies rich in NPY and Y5R, such as neuroblastoma, breast and prostate cancer. Given availability of the FDA approved Y5R antagonist, NPY/Y5R pathway may be a promising target for therapies preventing cancer progression. Yet, further research is required to establish effectiveness of such pharmacological interventions.
Citation Format: Mina Adnani, Sung-Hyeok Hong, Susana Galli, Akanksha Mahajan, Nouran Abualsaud, Lindsay Caprio, Jason U. Tilan, Olga Rodriguez, Hingkun Wang, Christopher Albanese, Luciane R. Cavalli, Joanna Kitlinska. Neuropeptide Y as a metastatic factor [abstract]. In: Proceedings of the AACR Special Conference: Cancer Metastasis; 2022 Nov 14-17; Portland, OR. Philadelphia (PA): AACR; Cancer Res 2022;83(2 Suppl_2):Abstract nr PR018.
Collapse
|
6
|
Lyons T, Kekedjian C, Glaser P, Ohlin CA, van Eldik R, Rodriguez O, Albanese C, Van Keuren E, Stoll SL. Molecular Parameters Promoting High Relaxivity in Cluster-Nanocarrier Magnetic Resonance Imaging Contrast Agents. ACS Appl Mater Interfaces 2022; 14:10.1021/acsami.2c12584. [PMID: 36283049 PMCID: PMC10502962 DOI: 10.1021/acsami.2c12584] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/16/2023]
Abstract
We have investigated the mechanism of relaxivity for two magnetic resonance imaging contrast agents that both employ a cluster-nanocarrier design. The first system termed Mn8Fe4-coPS comprises the cluster Mn8Fe4O12(L)16(H2O)4 or Mn8Fe4 (1) (L = carboxylate) co-polymerized with polystyrene to form ∼75 nm nanobeads. The second system termed Mn3Bpy-PAm used the cluster Mn3(O2CCH3)6(Bpy)2 or Mn3Bpy (2) where Bpy = 2,2'-bipyridine, entrapped in ∼180 nm polyacrylamide nanobeads. Here, we investigate the rate of water exchange of the two clusters, and corresponding cluster-nanocarriers, in order to elucidate the mechanism of relaxivity in the cluster-nanocarrier. Swift-Connick analysis of O-17 NMR was used to determine the water exchange rates of the clusters and cluster-nanocarriers. We found distinct differences in the water exchange rate between Mn8Fe4 and Mn8Fe4-coPS, and we utilized these differences to elucidate the nanobead structure. Using the transverse relaxivity from O-17 NMR line widths, we were able to determine the hydration state of the Mn3Bpy (2) cluster as well as Mn3Bpy-PAm. Using these hydration states in the Swift-Connick analysis of O-17 NMR, we found the water exchange rate to be extremely close in value for the cluster Mn3Bpy and cluster-nanocarrier Mn3Bpy-PAm.
Collapse
Affiliation(s)
- Trevor Lyons
- Department of Chemistry, Georgetown University, 37th and O Streets NW, Washington, D.C.20057, United States
| | - Chloe Kekedjian
- Department of Chemistry, Georgetown University, 37th and O Streets NW, Washington, D.C.20057, United States
| | - Priscilla Glaser
- Department of Chemistry, Georgetown University, 37th and O Streets NW, Washington, D.C.20057, United States
| | - C André Ohlin
- Department of Chemistry, Umeå University, Umeå907 36, Sweden
| | - Rudi van Eldik
- Faculty of Chemistry, Nicolaus Copernicus University, Torun87 100, Poland
- Inorganic Chemistry, Department of Chemistry and Pharmacy, University of Erlangen-Nuremberg, Egerlandstrasse 1, Erlangen91058, Germany
| | - Olga Rodriguez
- Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, D.C.20057, United States
| | - Christopher Albanese
- Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, D.C.20057, United States
- Department of Radiology, Georgetown University Medical Center, Washington, D.C.20057, United States
| | - Edward Van Keuren
- Department of Physics, and Institute for Soft Matter Synthesis and Metrology, Georgetown University, 37th and O Streets NW, Washington, D.C.20057, United States
| | - Sarah L Stoll
- Department of Chemistry, Georgetown University, 37th and O Streets NW, Washington, D.C.20057, United States
| |
Collapse
|
7
|
Rodriguez O, Mahfoud F, Schmieder R, Schlaich M, Narkiewicz K, Ruilope L, Williams B, Fahy M, Mancia G, Boehm M. Blood pressure reduction in higher cardiovascular risk patients in the Global SYMPLICITY Registry. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.2209] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background/Introduction
The Global SYMPLICITY Registry (GSR) was designed to evaluate the safety and efficacy of renal denervation (RDN) in real-world patients. Inclusion and exclusion criteria are limited to allow assessment of the effects of RDN on patients with a wide range of comorbidities. The current analysis examines blood pressure (BP) reduction after RDN in higher cardiovascular risk patients.
Purpose
To evaluate blood pressure reduction after RDN in higher cardiovascular risk patients in GSR.
Methods
GSR is a prospective all-comers registry to evaluate the safety and efficacy of RDN. Patients are enrolled in GSR and receive radiofrequency RDN using the Symplicity Flex or Symplicity Spyral catheter. Office and ambulatory BP are measured at each follow-up (3, 6, 12, 24, and 36 months). In this post-hoc analysis, changes from baseline in office and 24-hour ambulatory systolic blood pressure were assessed in patients at higher cardiovascular risk. Higher risk was defined using baseline office systolic or diastolic BP as well as additional risk factors (Figure 1).
Results
As of March 2021, there were 2621 patients characterized as higher cardiovascular risk in GSR. Baseline characteristics included mean age 60.7±12.1 years, 57.6% male, 37.9% type 2 diabetes, 35.8% hypocholesterolemia, 19.7% eGFR <60 mL/min/1.73 m2, 16.2% left ventricular hypertrophy, 10.2% previous stroke and 9.3% previous myocardial infarction. Baseline office systolic BP (OSBP) was 168.8±22.7 mmHg and baseline ambulatory systolic BP (ASBP) 155.3±18.6 mmHg. Mean OSBP reductions after RDN in this higher risk population ranged from −13.1 mmHg at 3 months to −17.5 mmHg at 24 months and −18.9 mmHg at 36 months, and mean ASBP reductions ranged from −7.8 mmHg at 3 months to −9.8 mmHg at 24 months and −9.3 mmHg at 36 months (Figure).
Conclusions
Higher risk patients in GSR had sustained office and ambulatory systolic BP reductions out to 3 years after catheter-based radiofrequency RDN.
Funding Acknowledgement
Type of funding sources: Private company. Main funding source(s): Medtronic
Collapse
Affiliation(s)
- O Rodriguez
- Germans Trias i Pujol Hospital , Barcelona , Spain
| | - F Mahfoud
- University hospital of Saarland (UKS) , Homburg/Saar , Germany
| | - R Schmieder
- University Hospital Erlangen , Erlangen , Germany
| | - M Schlaich
- The University of Western Australia , Perth , Australia
| | | | - L Ruilope
- University Hospital 12 de Octubre , Madrid , Spain
| | - B Williams
- University College of London , London , United Kingdom
| | - M Fahy
- Medtronic , Santa Rosa , United States of America
| | - G Mancia
- University of Milan-Bicocca , Monza , Italy
| | - M Boehm
- University hospital of Saarland (UKS) , Homburg/Saar , Germany
| |
Collapse
|
8
|
Jafari S, Baum IS, Udalov OG, Lee Y, Rodriguez O, Fricke ST, Jafari M, Amini M, Probst R, Tang X, Chen C, Ariando DJ, Hevaganinge A, Mair LO, Albanese C, Weinberg IN. Opening the Blood Brain Barrier with an Electropermanent Magnet System. Pharmaceutics 2022; 14:1503. [PMID: 35890398 PMCID: PMC9317373 DOI: 10.3390/pharmaceutics14071503] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2022] [Revised: 07/15/2022] [Accepted: 07/18/2022] [Indexed: 12/03/2022] Open
Abstract
Opening the blood brain barrier (BBB) under imaging guidance may be useful for the treatment of many brain disorders. Rapidly applied magnetic fields have the potential to generate electric fields in brain tissue that, if properly timed, may enable safe and effective BBB opening. By tuning magnetic pulses generated by a novel electropermanent magnet (EPM) array, we demonstrate the opening of tight junctions in a BBB model culture in vitro, and show that induced monophasic electrical pulses are more effective than biphasic ones. We confirmed, with in vivo contrast-enhanced MRI, that the BBB can be opened with monophasic pulses. As electropermanent magnets have demonstrated efficacy at tuning B0 fields for magnetic resonance imaging studies, our results suggest the possibility of implementing an EPM-based hybrid theragnostic device that could both image the brain and enhance drug transport across the BBB in a single sitting.
Collapse
Affiliation(s)
- Sahar Jafari
- Weinberg Medical Physics, Inc., North Bethesda, MD 20852, USA; (S.J.); (I.S.B.); (O.G.U.); (X.T.); (C.C.); (A.H.); (L.O.M.)
| | - Ittai S. Baum
- Weinberg Medical Physics, Inc., North Bethesda, MD 20852, USA; (S.J.); (I.S.B.); (O.G.U.); (X.T.); (C.C.); (A.H.); (L.O.M.)
| | - Oleg G. Udalov
- Weinberg Medical Physics, Inc., North Bethesda, MD 20852, USA; (S.J.); (I.S.B.); (O.G.U.); (X.T.); (C.C.); (A.H.); (L.O.M.)
| | - Yichien Lee
- Department of Oncology, Georgetown University Medical Center, Washington, DC 20057, USA; (Y.L.); (O.R.); (S.T.F.); (C.A.)
| | - Olga Rodriguez
- Department of Oncology, Georgetown University Medical Center, Washington, DC 20057, USA; (Y.L.); (O.R.); (S.T.F.); (C.A.)
- Center for Translational Imaging, Georgetown University Medical Center, Washington, DC 20057, USA
| | - Stanley T. Fricke
- Department of Oncology, Georgetown University Medical Center, Washington, DC 20057, USA; (Y.L.); (O.R.); (S.T.F.); (C.A.)
- Center for Translational Imaging, Georgetown University Medical Center, Washington, DC 20057, USA
- Department of Radiology, Georgetown University Medical Center, Washington, DC 20057, USA
| | - Maryam Jafari
- Independent Consultant, Oklahoma City, OK 73134, USA;
| | - Mostafa Amini
- Department of Management Science and Information Systems, Oklahoma State University, Stillwater, OK 74078, USA;
| | | | - Xinyao Tang
- Weinberg Medical Physics, Inc., North Bethesda, MD 20852, USA; (S.J.); (I.S.B.); (O.G.U.); (X.T.); (C.C.); (A.H.); (L.O.M.)
| | - Cheng Chen
- Weinberg Medical Physics, Inc., North Bethesda, MD 20852, USA; (S.J.); (I.S.B.); (O.G.U.); (X.T.); (C.C.); (A.H.); (L.O.M.)
| | - David J. Ariando
- Department of Electrical and Computer Engineering, University of Florida, Gainesville, FL 32611, USA;
| | - Anjana Hevaganinge
- Weinberg Medical Physics, Inc., North Bethesda, MD 20852, USA; (S.J.); (I.S.B.); (O.G.U.); (X.T.); (C.C.); (A.H.); (L.O.M.)
| | - Lamar O. Mair
- Weinberg Medical Physics, Inc., North Bethesda, MD 20852, USA; (S.J.); (I.S.B.); (O.G.U.); (X.T.); (C.C.); (A.H.); (L.O.M.)
| | - Christopher Albanese
- Department of Oncology, Georgetown University Medical Center, Washington, DC 20057, USA; (Y.L.); (O.R.); (S.T.F.); (C.A.)
- Center for Translational Imaging, Georgetown University Medical Center, Washington, DC 20057, USA
- Department of Radiology, Georgetown University Medical Center, Washington, DC 20057, USA
| | - Irving N. Weinberg
- Weinberg Medical Physics, Inc., North Bethesda, MD 20852, USA; (S.J.); (I.S.B.); (O.G.U.); (X.T.); (C.C.); (A.H.); (L.O.M.)
| |
Collapse
|
9
|
Bhatia S, Nguyen D, Darragh LB, Van Court B, Sharma J, Knitz MW, Piper M, Bukkapatnam S, Gadwa J, Bickett TE, Bhuvane S, Corbo S, Wu B, Lee Y, Fujita M, Joshi M, Heasley LE, Ferris RL, Rodriguez O, Albanese C, Kapoor M, Pasquale EB, Karam SD. EphB4 and ephrinB2 act in opposition in the head and neck tumor microenvironment. Nat Commun 2022; 13:3535. [PMID: 35725568 PMCID: PMC9209511 DOI: 10.1038/s41467-022-31124-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2021] [Accepted: 06/06/2022] [Indexed: 01/14/2023] Open
Abstract
Differential outcomes of EphB4-ephrinB2 signaling offers formidable challenge for the development of cancer therapeutics. Here, we interrogate the effects of targeting EphB4 and ephrinB2 in head and neck squamous cell carcinoma (HNSCC) and within its microenvironment using genetically engineered mice, recombinant constructs, pharmacologic agonists and antagonists. We observe that manipulating the EphB4 intracellular domain on cancer cells accelerates tumor growth and angiogenesis. EphB4 cancer cell loss also triggers compensatory upregulation of EphA4 and T regulatory cells (Tregs) influx and their targeting results in reversal of accelerated tumor growth mediated by EphB4 knockdown. EphrinB2 knockout on cancer cells and vasculature, on the other hand, results in maximal tumor reduction and vascular normalization. We report that EphB4 agonism provides no additional anti-tumoral benefit in the absence of ephrinB2. These results identify ephrinB2 as a tumor promoter and its receptor, EphB4, as a tumor suppressor in HNSCC, presenting opportunities for rational drug design.
Collapse
Affiliation(s)
- Shilpa Bhatia
- Department of Radiation Oncology, University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, USA
| | - Diemmy Nguyen
- Department of Radiation Oncology, University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, USA
| | - Laurel B Darragh
- Department of Radiation Oncology, University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, USA
| | - Benjamin Van Court
- Department of Radiation Oncology, University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, USA
| | - Jaspreet Sharma
- Department of Radiation Oncology, University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, USA
| | - Michael W Knitz
- Department of Radiation Oncology, University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, USA
| | - Miles Piper
- Department of Radiation Oncology, University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, USA
| | - Sanjana Bukkapatnam
- Department of Radiation Oncology, University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, USA
| | - Jacob Gadwa
- Department of Radiation Oncology, University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, USA
| | - Thomas E Bickett
- Department of Radiation Oncology, University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, USA
| | - Shiv Bhuvane
- Department of Radiation Oncology, University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, USA
| | - Sophia Corbo
- Department of Radiation Oncology, University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, USA
| | - Brian Wu
- Krembil Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada
| | - Yichien Lee
- Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA
| | - Mayumi Fujita
- Department of Dermatology, University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, USA
| | - Molishree Joshi
- Department of Pharmacology, University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, USA
| | - Lynn E Heasley
- Department of Craniofacial Biology, School of Dental Medicine, University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, USA
| | - Robert L Ferris
- Department of Otolaryngology, University of Pittsburgh, Pittsburgh, PA, USA
- Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
- UPMC Hillman Cancer Center, Pittsburgh, PA, USA
| | - Olga Rodriguez
- Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA
| | - Christopher Albanese
- Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA
| | - Mohit Kapoor
- Krembil Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada
| | - Elena B Pasquale
- Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA
| | - Sana D Karam
- Department of Radiation Oncology, University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, USA.
| |
Collapse
|
10
|
Choos END, Rodriguez O, Albanese C, Ecelbarger CM, Shepard BD. Characterizing Hepatic Inflammation upon SGLT2 Inhibition in Diabetic TallyHo Mice. FASEB J 2022. [DOI: 10.1096/fasebj.2022.36.s1.r4725] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
11
|
Souza A, Ji H, Korolowicz K, Rodriguez O, Albanese C, Ecelbarger C, Sandberg K. Yo‐Yo Diet Has Adverse Effects on Cardiac Function and Insulin Sensitivity in Female Fischer Rats. FASEB J 2022. [DOI: 10.1096/fasebj.2022.36.s1.r5866] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
| | - Hong Ji
- MedicineGeorgetown UniversityWashingtonDC
| | | | | | | | | | | |
Collapse
|
12
|
Wang G, Rebeck GW, Rodriguez O, Lippman ME, Bishopric NH. Abstract P1-08-05: Expression of the human APOE4 genotype modulates Doxorubicin cardiotoxicity in mice. Cancer Res 2022. [DOI: 10.1158/1538-7445.sabcs21-p1-08-05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: The human apolipoprotein E (APOE) gene has three major allelic variants: APOE2, -E3 and -E4. Carriers of the E4 allele are at increased risk for Alzheimer’s and other age-related neurodegenerative disorders. Recently, APOE4 has been associated with risk for cancer-related cognitive decline following chemotherapy with Doxorubicin (DOX), a frequent component of adjuvant therapy for breast cancer. To date, the mechanisms for APOE4 neurotoxicity are unknown, but may greater vulnerability to oxidative stress. DOX also causes dose-dependent cardiotoxicity, but a role for APOE4 in heart damage has not been previously demonstrated. Objective: To determine whether APOE4 predisposes to DOX-induced damage to the myocardium. Methods: C57Bl/6 mice (5-7 mo and 14-18 mo, male and female) with human APOE3 or APOE4 homozygous knock-in (=hAPOE3 and hAPOE4, respectively) were subjected to a single IP injection of saline (Control) or DOX (10 mg/kg, or 5 weekly injections of 5 mg/kg, =DOX), and monitored between 3-45 days afterward. Left ventricular systolic function was quantitated using echocardiography (Vevo 3100) at baseline, during and at the end of each study. TUNEL assay was used to identify apoptotic cells. Collagen was imaged using Masson’s Trichrome staining. Myocardial protein and RNA were extracted from the left ventricle and was analyzed by immunoblotting, realtime PCR and RNASeq on an Illumina NexGen platform.Results: Aged female APOE4 mice had more myocardial collagen at baseline (8.93±1.23 vs. 6.06±1.44%). Baseline cardiac function were similar at baseline in the 2 mouse strains. Three days after DOX, apoptotic myocytes were more abundant in hAPOE4 vs hAPOE3 hearts (1.2 vs. 4.6 TUNEL+ cells per section, n= 5, p<0.05). After DOX treatment, hAPOE4 mice had greater declines in left ventricular ejection fraction (EF, 46.9 vs 62.1%, p = hAPOE4 vs hAPOE3, p < 0.001). Quantitative PCR, RNASeq and protein studies revealed multiple differences in the cardiac transcriptome between hAPOE3 and hAPOE4 mice both at baseline and after DOX treatment. Baseline expression of MEF2D, a key driver of the myocardial stress response, was increased in hAPOE4 vs APOE3, driven by a 3500x (p = 4.76E-17) in transcript variant 1. Robust differences were seen in expression of c-Jun, JunB, and myosin heavy chain genes Myh6 and Myh7 at baseline and following DOX treatment at day 3. Growth Arrest And DNA Damage Inducible Alpha(GADD45A) gene expression was ~2x higher in hAPOE4 mice at baseline, but was similar to hAPOE3 mice by day 14 after DOX. Protein levels of caspase-1, an essential regulator of inflammation and the innate immune response, increased with age in hAPOE3 mice. In contrast, levels of casp-1 were lower in hAPOE4 and did not increase with age (p= 0.002 for APOE4 vs APOE3 at 17 mo). Conclusions: These findings support a model in which the APOE4 allele increases vulnerability to DOX-induced cardiac damage through mechanisms that involve significant and complex alterations in the response to oxidative stress and/or damage signaling. Studies are ongoing to further elucidate transcriptional differences conferred by APOE4, to analyze substrates downstream of caspase-1 affected by APOE4, and to determine the extent to which APOE4 may contribute to DOX toxicity in patient populations.
Citation Format: Guannan Wang, G. William Rebeck, Olga Rodriguez, Marc E. Lippman, Nanette H. Bishopric. Expression of the human APOE4 genotype modulates Doxorubicin cardiotoxicity in mice [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P1-08-05.
Collapse
Affiliation(s)
- Guannan Wang
- Georgetown Lombardi Comprehensive Cancer Center, Washington, DC
| | | | - Olga Rodriguez
- Georgetown Lombardi Comprehensive Cancer Center, Washington, DC
| | - Marc E. Lippman
- Georgetown Lombardi Comprehensive Cancer Center, Washington, DC
| | | |
Collapse
|
13
|
Naeem A, Harish V, Coste S, Parasido EM, Choudhry MU, Kromer LF, Ihemelandu C, Petricoin EF, Pierobon M, Noon MS, Yenugonda VM, Avantaggiati M, Kupfer GM, Fricke S, Rodriguez O, Albanese C. Regulation of Chemosensitivity in Human Medulloblastoma Cells by p53 and the PI3 Kinase Signaling Pathway. Mol Cancer Res 2022; 20:114-126. [PMID: 34635507 PMCID: PMC8738155 DOI: 10.1158/1541-7786.mcr-21-0277] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2021] [Revised: 07/06/2021] [Accepted: 10/04/2021] [Indexed: 01/07/2023]
Abstract
In medulloblastoma, p53 expression has been associated with chemoresistance and radiation resistance and with poor long-term outcomes in the p53-mutated sonic hedgehog, MYC-p53, and p53-positive medulloblastoma subgroups. We previously established a direct role for p53 in supporting drug resistance in medulloblastoma cells with high basal protein expression levels (D556 and DAOY). We now show that p53 genetic suppression in medulloblastoma cells with low basal p53 protein expression levels (D283 and UW228) significantly reduced drug responsiveness, suggesting opposing roles for low p53 protein expression levels. Mechanistically, the enhanced cell death by p53 knockdown in high-p53 cells was associated with an induction of mTOR/PI3K signaling. Both mTOR inhibition and p110α/PIK3CA induction confirmed these findings, which abrogated or accentuated the enhanced chemosensitivity response in D556 cells respectively while converse was seen in D283 cells. Co-treatment with G-actin-sequestering peptide, thymosin β4 (Tβ4), induced p-AKTS473 in both p53-high and p53-low cells, enhancing chemosensitivity in D556 cells while enhancing chemoresistance in D283 and UW228 cells. IMPLICATIONS: Collectively, we identified an unexpected role for the PI3K signaling in enhancing cell death in medulloblastoma cells with high basal p53 expression. These studies indicate that levels of p53 immunopositivity may serve as a diagnostic marker of chemotherapy resistance and for defining therapeutic targeting.
Collapse
Affiliation(s)
- Aisha Naeem
- Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC.,Health Research Governance Department, Ministry of Public Health, Doha, Qatar
| | - Varsha Harish
- Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC
| | - Sophie Coste
- Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC
| | - Erika M. Parasido
- Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC
| | - Muhammad Umer Choudhry
- Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC
| | - Lawrence F. Kromer
- Department of Neuroscience, Georgetown University Medical Center, Washington, DC
| | - Chukuemeka Ihemelandu
- Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC
| | - Emanuel F. Petricoin
- George Mason University, Center for Applied Proteomics and Molecular Medicine, Manassas, Virginia
| | - Mariaelena Pierobon
- George Mason University, Center for Applied Proteomics and Molecular Medicine, Manassas, Virginia
| | | | | | - Maria Avantaggiati
- Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC
| | - Gary M. Kupfer
- Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC.,Department of Pediatrics, Georgetown University Medical Center, Washington, DC
| | - Stanley Fricke
- Department of Radiology, Georgetown University Medical Center, Washington, DC.,Center for Translational Imaging, Georgetown University Medical Center, Washington, DC
| | - Olga Rodriguez
- Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC.,Center for Translational Imaging, Georgetown University Medical Center, Washington, DC
| | - Chris Albanese
- Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC.,Department of Radiology, Georgetown University Medical Center, Washington, DC.,Center for Translational Imaging, Georgetown University Medical Center, Washington, DC.,Corresponding Author: Chris Albanese, Department of OncologyGeorgetown University Medical Center, Lombardi Cancer Center, NRB W417, Washington, DC 20007. Phone: 202-687-3305; E-mail:
| |
Collapse
|
14
|
Liggett JR, Kang J, Ranjit S, Rodriguez O, Loh K, Patil D, Cui Y, Duttargi A, Nguyen S, He B, Lee Y, Oza K, Frank BS, Kwon D, Li HH, Kallakury B, Libby A, Levi M, Robson SC, Fishbein TM, Cui W, Albanese C, Khan K, Kroemer A. Oral N-acetylcysteine decreases IFN-γ production and ameliorates ischemia-reperfusion injury in steatotic livers. Front Immunol 2022; 13:898799. [PMID: 36148239 PMCID: PMC9486542 DOI: 10.3389/fimmu.2022.898799] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2022] [Accepted: 07/11/2022] [Indexed: 12/05/2022] Open
Abstract
Type 1 Natural Killer T-cells (NKT1 cells) play a critical role in mediating hepatic ischemia-reperfusion injury (IRI). Although hepatic steatosis is a major risk factor for preservation type injury, how NKT cells impact this is understudied. Given NKT1 cell activation by phospholipid ligands recognized presented by CD1d, we hypothesized that NKT1 cells are key modulators of hepatic IRI because of the increased frequency of activating ligands in the setting of hepatic steatosis. We first demonstrate that IRI is exacerbated by a high-fat diet (HFD) in experimental murine models of warm partial ischemia. This is evident in the evaluation of ALT levels and Phasor-Fluorescence Lifetime (Phasor-FLIM) Imaging for glycolytic stress. Polychromatic flow cytometry identified pronounced increases in CD45+CD3+NK1.1+NKT1 cells in HFD fed mice when compared to mice fed a normal diet (ND). This observation is further extended to IRI, measuring ex vivo cytokine expression in the HFD and ND. Much higher interferon-gamma (IFN-γ) expression is noted in the HFD mice after IRI. We further tested our hypothesis by performing a lipidomic analysis of hepatic tissue and compared this to Phasor-FLIM imaging using "long lifetime species", a byproduct of lipid oxidation. There are higher levels of triacylglycerols and phospholipids in HFD mice. Since N-acetylcysteine (NAC) is able to limit hepatic steatosis, we tested how oral NAC supplementation in HFD mice impacted IRI. Interestingly, oral NAC supplementation in HFD mice results in improved hepatic enhancement using contrast-enhanced magnetic resonance imaging (MRI) compared to HFD control mice and normalization of glycolysis demonstrated by Phasor-FLIM imaging. This correlated with improved biochemical serum levels and a decrease in IFN-γ expression at a tissue level and from CD45+CD3+CD1d+ cells. Lipidomic evaluation of tissue in the HFD+NAC mice demonstrated a drastic decrease in triacylglycerol, suggesting downregulation of the PPAR-γ pathway.
Collapse
Affiliation(s)
- Jedson R Liggett
- MedStar Georgetown Transplant Institute, MedStar Georgetown University Hospital and the Center for Translational Transplant Medicine, Georgetown University Medical Center, Washington, DC, United States.,Department of Surgery, Naval Medical Center Portsmouth, Portsmouth, VA, United States
| | - Jiman Kang
- MedStar Georgetown Transplant Institute, MedStar Georgetown University Hospital and the Center for Translational Transplant Medicine, Georgetown University Medical Center, Washington, DC, United States.,Department of Biochemistry and Molecular & Cellular Biology, Georgetown University, Washington, DC, United States
| | - Suman Ranjit
- Department of Biochemistry and Molecular & Cellular Biology, Georgetown University, Washington, DC, United States.,Microscopy & Imaging Shared Resource, Georgetown University, Washington, DC, United States
| | - Olga Rodriguez
- Center for Translational Imaging, Georgetown University Medical Center, Washington, DC, United States.,Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, United States
| | - Katrina Loh
- MedStar Georgetown Transplant Institute, MedStar Georgetown University Hospital and the Center for Translational Transplant Medicine, Georgetown University Medical Center, Washington, DC, United States
| | - Digvijay Patil
- MedStar Georgetown Transplant Institute, MedStar Georgetown University Hospital and the Center for Translational Transplant Medicine, Georgetown University Medical Center, Washington, DC, United States
| | - Yuki Cui
- MedStar Georgetown Transplant Institute, MedStar Georgetown University Hospital and the Center for Translational Transplant Medicine, Georgetown University Medical Center, Washington, DC, United States
| | - Anju Duttargi
- Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, United States
| | - Sang Nguyen
- Center for Translational Imaging, Georgetown University Medical Center, Washington, DC, United States
| | - Britney He
- Center for Translational Imaging, Georgetown University Medical Center, Washington, DC, United States
| | - Yichien Lee
- Center for Translational Imaging, Georgetown University Medical Center, Washington, DC, United States.,Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, United States
| | - Kesha Oza
- MedStar Georgetown Transplant Institute, MedStar Georgetown University Hospital and the Center for Translational Transplant Medicine, Georgetown University Medical Center, Washington, DC, United States
| | - Brett S Frank
- MedStar Georgetown Transplant Institute, MedStar Georgetown University Hospital and the Center for Translational Transplant Medicine, Georgetown University Medical Center, Washington, DC, United States
| | - DongHyang Kwon
- Department of Pathology, MedStar Georgetown University Hospital, Washington, DC, United States
| | - Heng-Hong Li
- Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, United States
| | - Bhaskar Kallakury
- Department of Pathology, MedStar Georgetown University Hospital, Washington, DC, United States
| | - Andrew Libby
- Division of Endocrinology, Metabolism, & Diabetes, University of Colorado Anschutz Medical Campus, Aurora, CO, United States
| | - Moshe Levi
- Department of Biochemistry and Molecular & Cellular Biology, Georgetown University, Washington, DC, United States
| | - Simon C Robson
- Departments of Anesthesiology and Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States
| | - Thomas M Fishbein
- MedStar Georgetown Transplant Institute, MedStar Georgetown University Hospital and the Center for Translational Transplant Medicine, Georgetown University Medical Center, Washington, DC, United States
| | - Wanxing Cui
- MedStar Georgetown Transplant Institute, MedStar Georgetown University Hospital and the Center for Translational Transplant Medicine, Georgetown University Medical Center, Washington, DC, United States.,Department of Biochemistry and Molecular & Cellular Biology, Georgetown University, Washington, DC, United States
| | - Chris Albanese
- Center for Translational Imaging, Georgetown University Medical Center, Washington, DC, United States.,Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, United States.,Department of Radiology, MedStar Georgetown University Hospital, Washington, DC, United States
| | - Khalid Khan
- MedStar Georgetown Transplant Institute, MedStar Georgetown University Hospital and the Center for Translational Transplant Medicine, Georgetown University Medical Center, Washington, DC, United States
| | - Alexander Kroemer
- MedStar Georgetown Transplant Institute, MedStar Georgetown University Hospital and the Center for Translational Transplant Medicine, Georgetown University Medical Center, Washington, DC, United States
| |
Collapse
|
15
|
Sánchez-Guixé M, Hierro C, Jiménez J, Viaplana C, Villacampa G, Monelli E, Brasó-Maristany F, Ogbah Z, Parés M, Guzmán M, Grueso J, Rodriguez O, Oliveira M, Azaro A, Garralda E, Tabernero J, Casanovas O, Scaltriti M, Prat A, Dienstmann R, Nuciforo P, Saura C, Graupera M, Vivancos A, Rodon J, Serra V. High FGFR1-4 mRNA expression levels correlate with response to selective FGFR inhibitors in breast cancer. Clin Cancer Res 2021; 28:137-149. [PMID: 34593528 DOI: 10.1158/1078-0432.ccr-21-1810] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2021] [Revised: 08/02/2021] [Accepted: 09/27/2021] [Indexed: 11/16/2022]
Abstract
PURPOSE FGFR1 amplification (FGFR1amp) is recurrent in metastatic breast cancer (BC) and is associated with resistance to endocrine therapy (ET) and CDK4/6 inhibitors (CDK4/6i). Multi-tyrosine kinase inhibitors (MTKI) and selective pan-FGFR inhibitors (FGFRi) are being developed for FGFR1amp BC. High-level FGFR amplification and protein expression by IHC have identified BC responders to FGFRi or MTKI, respectively. EXPERIMENTAL DESIGN Here, we used preclinical models and patient samples to identify predictive biomarkers to these drugs. We evaluated the antitumor activity of an FGFRi and an MTKI in a collection of seventeen BC patient-derived xenografts (PDXs) harboring amplification in FGFR1/2/3/4 and in ten patients receiving either an FGFRi/MTKI. mRNA levels were measured on FFPE tumor samples using two commercial strategies. Proliferation and angiogenesis were evaluated by detecting Ki-67 and CD31 in viable areas by immunofluorescence. RESULTS High FGFR1-4 mRNA levels but not copy number alteration (CNA) associated with FGFRi response. Treatment with MTKI showed higher response rates than with FGFRi (86% vs 53%), regardless of the FGFR1-4 mRNA levels. FGFR-addicted PDXs exhibited an antiproliferative response to either FGFRi or MTKI, and PDXs exclusively sensitive to MTKI exhibited an additional anti-angiogenic response. Consistently, clinical benefit of MTKI was not associated with high FGFR1-4 mRNA levels and it was observed in patients previously treated with anti-angiogenic drugs. CONCLUSION Tailored therapy with FGFRi in molecularly-selected metastatic BC based on high FGFR1-4 mRNA levels warrants prospective validation in luminal BC CDK4/6i-resistant patients and in TNBC patients without targeted therapeutic options.
Collapse
Affiliation(s)
| | - Cinta Hierro
- Department of Medical Oncology, Vall d'Hebron University Hospital. Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
| | - José Jiménez
- Molecular Pathology, Vall d'Hebron Institute of Oncology
| | - Cristina Viaplana
- Oncology Data Science Group, Vall d'Hebron Institute of Oncology (VHIO)
| | | | - Erika Monelli
- Angiogenesis Unit, Institut d'Investigació Biomèdica de Bellvitge
| | | | - Zighereda Ogbah
- Cancer Genomic Group, Vall Hebron Institute of Oncology (VHIO)
| | - Mireia Parés
- Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology
| | - Marta Guzmán
- Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology
| | - Judit Grueso
- Experimental Therapeutics Laboratory, Vall d'Hebron Institute of Oncology (VHIO)
| | - Olga Rodriguez
- Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology
| | - Mafalda Oliveira
- Medical Oncology, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO)
| | - Analía Azaro
- Molecular Therapeutics Research Unit, Oncology Department, Vall d'Hebron University Hospital
| | | | - Josep Tabernero
- Medical Oncology Department, Vall d'Hebron University Hospital
| | | | | | - Aleix Prat
- Department of Medical Oncology, Hospital Clinic de Barcelona
| | - Rodrigo Dienstmann
- Medical Oncology - Oncology Data Science, Vall d'Hebron Institute of Oncology
| | - Paolo Nuciforo
- Molecular Oncology, Vall d'Hebron Institute of Oncology (VHIO)
| | - Cristina Saura
- Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, Medical Oncology Department; SOLTI Breast Cancer Research Group
| | - Mariona Graupera
- ProCURE, Oncobell Program, Institut d�'Investigació Biomèdica de Bellvitge
| | - Ana Vivancos
- Cancer Genomic Group, Vall d'Hebron Institute of Oncology (VHIO)
| | - Jordi Rodon
- Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center
| | - Violeta Serra
- Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology (VHIO)
| |
Collapse
|
16
|
Dahanayake V, Lyons T, Kerwin B, Rodriguez O, Albanese C, Parasido E, Lee Y, Keuren EV, Li L, Maxey E, Paunesku T, Woloschak G, Stoll SL. Paramagnetic Mn 8Fe 4- co-Polystyrene Nanobeads as a Potential T 1-T 2 Multimodal Magnetic Resonance Imaging Contrast Agent with In Vivo Studies. ACS Appl Mater Interfaces 2021; 13:39042-39054. [PMID: 34375073 PMCID: PMC10506655 DOI: 10.1021/acsami.1c09232] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/13/2023]
Abstract
In developing a cluster-nanocarrier design, as a magnetic resonance imaging contrast agent, we have investigated the enhanced relaxivity of a manganese and iron-oxo cluster grafted within a porous polystyrene nanobead with increased relaxivity due to a higher surface area. The synthesis of the cluster-nanocarrier for the cluster Mn8Fe4O12(O2CC6H4CH═CH2)16(H2O)4, cross-linked with polystyrene (the nanocarrier), under miniemulsion conditions is described. By including a branched hydrophobe, iso-octane, the resulting nanobeads are porous and ∼70 nm in diameter. The increased surface area of the nanobeads compared to nonporous nanobeads leads to an enhancement in relaxivity; r1 increases from 3.8 to 5.2 ± 0.1 mM-1 s-1, and r2 increases from 11.9 to 50.1 ± 4.8 mM-1 s-1, at 9.4 teslas, strengthening the potential for T1 and T2 imaging. Several metrics were used to assess stability, and the porosity produced no reduction in metal stability. Synchrotron X-ray fluorescence microscopy was used to demonstrate that the nanobeads remain intact in vivo. In depth, physicochemical characteristics were determined, including extensive pharmacokinetics, in vivo imaging, and systemic biodistribution analysis.
Collapse
Affiliation(s)
- Vidumin Dahanayake
- Department of Chemistry, Georgetown University, 37th and O Streets NW, Washington, D.C. 20057, United States
| | - Trevor Lyons
- Department of Chemistry, Georgetown University, 37th and O Streets NW, Washington, D.C. 20057, United States
| | - Brendan Kerwin
- Department of Chemistry, Georgetown University, 37th and O Streets NW, Washington, D.C. 20057, United States
| | - Olga Rodriguez
- Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, D.C. 20057, United States
| | - Christopher Albanese
- Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, D.C. 20057, United States
- Department of Radiology, Georgetown University Medical Center, Washington, D.C. 20057, United States
| | - Erika Parasido
- Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, D.C. 20057, United States
| | - Yichien Lee
- Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, D.C. 20057, United States
| | - Edward Van Keuren
- Department of Physics and Institute for Soft Matter Synthesis and Metrology, Georgetown University, 37th and O Streets NW, Washington, D.C. 20057, United States
| | - Luxi Li
- X-ray Science Division, Advanced Photon Source, Argonne National Laboratory, 9700 South Cass Avenue, Argonne, Illinois 60439, United States
| | - Evan Maxey
- X-ray Science Division, Advanced Photon Source, Argonne National Laboratory, 9700 South Cass Avenue, Argonne, Illinois 60439, United States
| | - Tatjana Paunesku
- Department of Radiation Oncology, Northwestern University, 303 E. Chicago Ave., Chicago, Illinois 60611, United States
| | - Gayle Woloschak
- Department of Radiation Oncology, Northwestern University, 303 E. Chicago Ave., Chicago, Illinois 60611, United States
| | - Sarah L Stoll
- Department of Chemistry, Georgetown University, 37th and O Streets NW, Washington, D.C. 20057, United States
| |
Collapse
|
17
|
Neckel ND, Dai H, Hanckel J, Lee Y, Albanese C, Rodriguez O. Skilled reach training enhances robotic gait training to restore overground locomotion following spinal cord injury in rats. Behav Brain Res 2021; 414:113490. [PMID: 34358574 DOI: 10.1016/j.bbr.2021.113490] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2021] [Revised: 07/23/2021] [Accepted: 07/25/2021] [Indexed: 10/20/2022]
Abstract
Rehabilitative training has been shown to improve motor function following spinal cord injury (SCI). Unfortunately, these gains are primarily task specific; where reach training only improves reaching, step training only improves stepping and stand training only improves standing. More troublesome is the tendency that the improvement in a trained task often comes at the expense of an untrained task. However, the task specificity of training does not preclude the benefits of combined rehabilitative training. Here we show that robot assisted gait training alone can partially reduce the deficits in unassisted overground locomotion following a C4/5 overhemisection injury in rats. When robot-assisted gait training is done in conjunction with skilled forelimb training, we observe a much greater level of recovery of unassisted overground locomotion. In order to provide reach training that would not interfere with our robotic gait training schedule, we prompted rats to increase the use of their forelimbs by replacing the standard overhead feeder with a custom made, deep welled hopper that dispensed nutritionally equivalent small milled pellets. We speculate that the increase in recovery from combined training is due to a more robust interneuronal relay network around the injury site. in vivo manganese-enhanced magnetic resonance imaging of the spinal cord indicated that there was no increase in the cellular activity, however ex vivo diffusion tensor imaging (DTI) suggested an increase in collateralization around the injury site in rats that received both reach training and robot assisted gait training.
Collapse
Affiliation(s)
- Nathan D Neckel
- Department of Neuroscience, Georgetown University, United States; Department of Rehabilitation Medicine, Georgetown University, United States.
| | - Haining Dai
- Department of Neuroscience, Georgetown University, United States
| | - John Hanckel
- Department of Neuroscience, Georgetown University, United States
| | - Yichien Lee
- Department of Oncology, Georgetown University, United States; Center for Translational Imaging, Georgetown University, United States
| | - Christopher Albanese
- Department of Oncology, Georgetown University, United States; Center for Translational Imaging, Georgetown University, United States
| | - Olga Rodriguez
- Department of Oncology, Georgetown University, United States; Center for Translational Imaging, Georgetown University, United States
| |
Collapse
|
18
|
Rouprêt M, Gontero P, Montanari E, Longo F, Witjes J, Dudderidge T, Stockley J, Kennedy A, Vanie F, Rodriguez O, Allasia M, Mccracken S, Sylvester R, Palou J. Anticipatory effects of ADXBLADDER test results in the follow up of cystoscopy negative non muscle invasive bladder cancer patients in a large multicentric European cohort. Eur Urol 2021. [DOI: 10.1016/s0302-2838(21)01100-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
19
|
Vilades Medel D, Bos L, Jimenez Kockar M, Altisent O, Rodriguez O, Alomar X, Schuijf J, Leta R. Impact of coronary atherosclerotic plaque metrics and CT reader skills on inter-observer variation of repeated on-site CT-FFR. Eur Heart J Cardiovasc Imaging 2021. [DOI: 10.1093/ehjci/jeaa356.249] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Funding Acknowledgements
Type of funding sources: None.
Background and Purpose
Little is known about the on-site CT-FFR inter-reader reproducibility and its variability in different atherosclerotic plaque scenarios. The aim of this study was to determine the variation of repeated CT-FFR analyses between two CCTA readers with different training skills across different atherosclerotic features.
Methods
Patients referred for invasive coronary angiography who accepted to undergo a CCTA/CT-FFR study were prospectively included. Patients with contraindications for CCTA, atrial fibrillation, chronic total occlusions or previous coronary revascularization were excluded. Quantification of atherosclerotic plaque metrics and CT-FFR was performed for each coronary vessel by two different CT readers, one Level I and one Level III. Inter-reader agreement for CT-FFR was assessed using kappa index, Bland-Altman and Lin’s concordance correlation agreement (LCCA). The impact of each atherosclerotic feature was assessed by dividing the dataset based on the corresponding median and assessing inter-reader variability for both the lower and upper half.
Results
47 patients (137 vessels) were included. Mean age was 66 ± 10 years, 89% were males, 63% had hypertension, 76% dyslipidemia and 38% diabetes. Degree of stenosis was moderate (50-69%) in 29% and severe (≥70%) in 28% of vessels with a positive CT-FFR (≤0.80) in 39%. CT-FFR showed good correlation between the two readers based on a kappa index of 0.77 with a mean CT-FFR difference of -0.017 ± 0.12. The inter-reader agreement was good in the main epicardial vessels (LCCA of 0.70 for LAD, 0.74 for LCX and 0.76 for RCA, p < 0.001 for all) and better in proximal than in distal segments (LCCA of 0.83 vs 0.63, p < 0.001). Likewise, in different atherosclerotic plaque scenarios, the agreement was better in those vessels with lower plaque volume, less calcified and longer lesions (see table 1).
Conclusions
In our cohort, on-site CT-FFR showed good inter-reader agreement without relevant impact by reader experience level and atherosclerotic plaque features.
Table 1 Mean difference Bland-Altman Lin’s concordance correlation coefficient p value Plaque volume < median (556 mm3) -0.01 ± 0.12 0.85 <0.001 Plaque volume > median (556 mm3) -0.035 ± 0.13 0.64 <0.001 Calcified plaque burden < median (34%) -0.03 ± 0.11 0.82 <0.001 Calcified plaque burden > median (34%) -0.02 ± 0.14 0.75 <0.001 Lesion length < median (55 mm) -0.005 ± 0.12 0.68 <0.001 Lesion length > median (55 mm) -0.031 ± 0.12 0.83 <0.001 *p values indicate inter-reader agreement by two independent observers for each category
Collapse
Affiliation(s)
- D Vilades Medel
- Hospital de la Santa Creu i Sant Pau, Department of Cardiology , Barcelona, Spain
| | - L Bos
- Hospital de la Santa Creu i Sant Pau, Department of Cardiology , Barcelona, Spain
| | - M Jimenez Kockar
- Hospital de la Santa Creu i Sant Pau, Department of Cardiology , Barcelona, Spain
| | - O Altisent
- Germans Trias i Pujol University Hospital, Interventional Cardiology, Barcelona, Spain
| | - O Rodriguez
- Germans Trias i Pujol University Hospital, Interventional Cardiology, Barcelona, Spain
| | - X Alomar
- Cl??nica Creu Blanca, Barcelona, Spain
| | - J Schuijf
- Canon Medical Systems Europe B.V, Zoetermeer, Netherlands (The)
| | - R Leta
- Hospital de la Santa Creu i Sant Pau, Department of Cardiology , Barcelona, Spain
| |
Collapse
|
20
|
Prasad S, Chandra A, Cavo M, Parasido E, Fricke S, Lee Y, D'Amone E, Gigli G, Albanese C, Rodriguez O, Del Mercato LL. Optical and magnetic resonance imaging approaches for investigating the tumour microenvironment: state-of-the-art review and future trends. Nanotechnology 2021; 32:062001. [PMID: 33065554 DOI: 10.1088/1361-6528/abc208] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/11/2023]
Abstract
The tumour microenvironment (TME) strongly influences tumorigenesis and metastasis. Two of the most characterized properties of the TME are acidosis and hypoxia, both of which are considered hallmarks of tumours as well as critical factors in response to anticancer treatments. Currently, various imaging approaches exist to measure acidosis and hypoxia in the TME, including magnetic resonance imaging (MRI), positron emission tomography and optical imaging. In this review, we will focus on the latest fluorescent-based methods for optical sensing of cell metabolism and MRI as diagnostic imaging tools applied both in vitro and in vivo. The primary emphasis will be on describing the current and future uses of systems that can measure intra- and extra-cellular pH and oxygen changes at high spatial and temporal resolution. In addition, the suitability of these approaches for mapping tumour heterogeneity, and assessing response or failure to therapeutics will also be covered.
Collapse
Affiliation(s)
- Saumya Prasad
- Institute of Nanotechnology, National Research Council (CNR-NANOTEC), c/o Campus Ecotekne, via Monteroni, 73100, Lecce, Italy
| | - Anil Chandra
- Institute of Nanotechnology, National Research Council (CNR-NANOTEC), c/o Campus Ecotekne, via Monteroni, 73100, Lecce, Italy
| | - Marta Cavo
- Institute of Nanotechnology, National Research Council (CNR-NANOTEC), c/o Campus Ecotekne, via Monteroni, 73100, Lecce, Italy
| | - Erika Parasido
- Department of Oncology, Georgetown University Medical Center, Washington, DC, United States of America
- Center for Translational Imaging, Georgetown University Medical Center, Washington, DC, United States of America
| | - Stanley Fricke
- Department of Oncology, Georgetown University Medical Center, Washington, DC, United States of America
- Center for Translational Imaging, Georgetown University Medical Center, Washington, DC, United States of America
- Department of Radiology, Georgetown University Medical Center, Washington, DC, United States of America
| | - Yichien Lee
- Department of Oncology, Georgetown University Medical Center, Washington, DC, United States of America
| | - Eliana D'Amone
- Institute of Nanotechnology, National Research Council (CNR-NANOTEC), c/o Campus Ecotekne, via Monteroni, 73100, Lecce, Italy
| | - Giuseppe Gigli
- Institute of Nanotechnology, National Research Council (CNR-NANOTEC), c/o Campus Ecotekne, via Monteroni, 73100, Lecce, Italy
- Department of Mathematics and Physics 'Ennio De Giorgi', University of Salento, via Arnesano, 73100, Lecce, Italy
| | - Chris Albanese
- Department of Oncology, Georgetown University Medical Center, Washington, DC, United States of America
- Center for Translational Imaging, Georgetown University Medical Center, Washington, DC, United States of America
- Department of Radiology, Georgetown University Medical Center, Washington, DC, United States of America
| | - Olga Rodriguez
- Department of Oncology, Georgetown University Medical Center, Washington, DC, United States of America
- Center for Translational Imaging, Georgetown University Medical Center, Washington, DC, United States of America
| | - Loretta L Del Mercato
- Institute of Nanotechnology, National Research Council (CNR-NANOTEC), c/o Campus Ecotekne, via Monteroni, 73100, Lecce, Italy
| |
Collapse
|
21
|
Gremmels H, Winkel BM, Schuurman R, Rosingh A, Rigter NA, Rodriguez O, Ubijaan J, Wensing AM, Bonten MJ, Hofstra L. Real-life validation of the Panbio™ COVID-19 antigen rapid test (Abbott) in community-dwelling subjects with symptoms of potential SARS-CoV-2 infection. EClinicalMedicine 2021; 31:100677. [PMID: 33521610 PMCID: PMC7832943 DOI: 10.1016/j.eclinm.2020.100677] [Citation(s) in RCA: 105] [Impact Index Per Article: 35.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/23/2020] [Revised: 11/23/2020] [Accepted: 11/24/2020] [Indexed: 01/06/2023] Open
Abstract
BACKGROUND RT-qPCR is the reference test for identification of active SARS-CoV-2 infection, but is associated with diagnostic delay. Antigen detection assays can generate results within 20 min and outside of laboratory settings. Yet, their diagnostic test performance in real life settings has not been determined. METHODS The diagnostic value of the Panbio™ COVID-19 Ag Rapid Test (Abbott), was determined in comparison to RT-qPCR (Seegene Allplex) in community-dwelling mildly symptomatic subjects in a medium (Utrecht, the Netherlands) and high endemic area (Aruba), using two concurrently obtained nasopharyngeal swabs.Findings: 1367 and 208 subjects were enrolled in Utrecht and Aruba, respectively. SARS-CoV-2 prevalence, based on RT-qPCR, was 10.2% (n = 139) and 30.3% (n = 63) in Utrecht and Aruba respectively. Specificity of the Panbio™ COVID-19 Ag Rapid Test was 100% (95%CI: 99.7-100%) in both settings. Test sensitivity was 72.6% (95%CI: 64.5-79.9%) in the Netherlands and 81.0% (95% CI: 69.0-89.8%) in Aruba. Probability of false negative results was associated with RT-qPCR Ct-values, but not with duration of symptoms. Restricting RT-qPCR test positivity to Ct-values <32 yielded test sensitivities of 95.2% (95%CI: 89.3-98.5%) in Utrecht and 98.0% (95%CI: 89.2-99.95%) in Aruba. INTERPRETATION In community-dwelling subjects with mild respiratory symptoms the Panbio™ COVID-19 Ag Rapid Test had 100% specificity, and a sensitivity above 95% for nasopharyngeal samples when using Ct-values <32 cycles as cut-off for RT-qPCR test positivity. Considering short turnaround times, user friendliness, low costs and opportunities for decentralized testing, this test can improve our efforts to control transmission of SARS-CoV-2.
Collapse
Affiliation(s)
- Hendrik Gremmels
- Department of Medical Microbiology, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX, Utrecht, the Netherlands
| | - Beatrice M.F. Winkel
- Department of Medical Microbiology, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX, Utrecht, the Netherlands
| | - Rob Schuurman
- Department of Medical Microbiology, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX, Utrecht, the Netherlands
| | - Andert Rosingh
- LABHOH, Fundacion Servicio Medico Laboratorio Aruba, Dr. Horacio E. Oduber Hospital, Boulevard 1, Oranjestad, Aruba
| | | | - Olga Rodriguez
- Dr. Horacio E. Oduber Hospital, Boulevard 1, Oranjestad, Aruba
| | - Johan Ubijaan
- LABHOH, Fundacion Servicio Medico Laboratorio Aruba, Dr. Horacio E. Oduber Hospital, Boulevard 1, Oranjestad, Aruba
| | - Annemarie M.J. Wensing
- Department of Medical Microbiology, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX, Utrecht, the Netherlands
| | - Marc J.M. Bonten
- Department of Medical Microbiology, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX, Utrecht, the Netherlands
| | - L.Marije Hofstra
- Department of Medical Microbiology, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX, Utrecht, the Netherlands
- Corresponding author.
| |
Collapse
|
22
|
Gremmels H, Winkel BM, Schuurman R, Rosingh A, Rigter NA, Rodriguez O, Ubijaan J, Wensing AM, Bonten MJ, Hofstra L. Real-life validation of the Panbio™ COVID-19 antigen rapid test (Abbott) in community-dwelling subjects with symptoms of potential SARS-CoV-2 infection. EClinicalMedicine 2020; 31:100677. [PMID: 33521610 PMCID: PMC7832943 DOI: 10.1016/j.eclinm.2020.100677;31:100677] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
Abstract
BACKGROUND RT-qPCR is the reference test for identification of active SARS-CoV-2 infection, but is associated with diagnostic delay. Antigen detection assays can generate results within 20 min and outside of laboratory settings. Yet, their diagnostic test performance in real life settings has not been determined. METHODS The diagnostic value of the Panbio™ COVID-19 Ag Rapid Test (Abbott), was determined in comparison to RT-qPCR (Seegene Allplex) in community-dwelling mildly symptomatic subjects in a medium (Utrecht, the Netherlands) and high endemic area (Aruba), using two concurrently obtained nasopharyngeal swabs.Findings: 1367 and 208 subjects were enrolled in Utrecht and Aruba, respectively. SARS-CoV-2 prevalence, based on RT-qPCR, was 10.2% (n = 139) and 30.3% (n = 63) in Utrecht and Aruba respectively. Specificity of the Panbio™ COVID-19 Ag Rapid Test was 100% (95%CI: 99.7-100%) in both settings. Test sensitivity was 72.6% (95%CI: 64.5-79.9%) in the Netherlands and 81.0% (95% CI: 69.0-89.8%) in Aruba. Probability of false negative results was associated with RT-qPCR Ct-values, but not with duration of symptoms. Restricting RT-qPCR test positivity to Ct-values <32 yielded test sensitivities of 95.2% (95%CI: 89.3-98.5%) in Utrecht and 98.0% (95%CI: 89.2-99.95%) in Aruba. INTERPRETATION In community-dwelling subjects with mild respiratory symptoms the Panbio™ COVID-19 Ag Rapid Test had 100% specificity, and a sensitivity above 95% for nasopharyngeal samples when using Ct-values <32 cycles as cut-off for RT-qPCR test positivity. Considering short turnaround times, user friendliness, low costs and opportunities for decentralized testing, this test can improve our efforts to control transmission of SARS-CoV-2.
Collapse
Affiliation(s)
- Hendrik Gremmels
- Department of Medical Microbiology, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX, Utrecht, the Netherlands
| | - Beatrice M.F. Winkel
- Department of Medical Microbiology, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX, Utrecht, the Netherlands
| | - Rob Schuurman
- Department of Medical Microbiology, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX, Utrecht, the Netherlands
| | - Andert Rosingh
- LABHOH, Fundacion Servicio Medico Laboratorio Aruba, Dr. Horacio E. Oduber Hospital, Boulevard 1, Oranjestad, Aruba
| | | | - Olga Rodriguez
- Dr. Horacio E. Oduber Hospital, Boulevard 1, Oranjestad, Aruba
| | - Johan Ubijaan
- LABHOH, Fundacion Servicio Medico Laboratorio Aruba, Dr. Horacio E. Oduber Hospital, Boulevard 1, Oranjestad, Aruba
| | - Annemarie M.J. Wensing
- Department of Medical Microbiology, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX, Utrecht, the Netherlands
| | - Marc J.M. Bonten
- Department of Medical Microbiology, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX, Utrecht, the Netherlands
| | - L.Marije Hofstra
- Department of Medical Microbiology, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX, Utrecht, the Netherlands
- Corresponding author.
| |
Collapse
|
23
|
Gontero P, Longo F, Allasia M, Roupret M, Stockley J, Kennedy A, Rodriguez O, Sieverink C, Vanie F, Witjes J, Colombel M, McCracken S, Dudderidge T, Sylvester R, Palou J, Montanari E. Comparison of performance of ADXBLADDER with urine cytology in NMIBC follow up: a blinded prospective multicentric study. EUR UROL SUPPL 2020. [DOI: 10.1016/s2666-1683(20)35622-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
24
|
Naeem A, Dakshanamurthy S, Walthieu H, Parasido E, Avantaggiati M, Tricoli L, Kumar D, Lee RJ, Feldman A, Noon MS, Byers S, Rodriguez O, Albanese C. Predicting new drug indications for prostate cancer: The integration of an in silico proteochemometric network pharmacology platform with patient-derived primary prostate cells. Prostate 2020; 80:1233-1243. [PMID: 32761925 PMCID: PMC7540414 DOI: 10.1002/pros.24050] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/20/2020] [Accepted: 07/21/2020] [Indexed: 12/13/2022]
Abstract
BACKGROUND Drug repurposing enables the discovery of potential cancer treatments using publically available data from over 4000 published Food and Drug Administration approved and experimental drugs. However, the ability to effectively evaluate the drug's efficacy remains a challenge. Impediments to broad applicability include inaccuracies in many of the computational drug-target algorithms and a lack of clinically relevant biologic modeling systems to validate the computational data for subsequent translation. METHODS We have integrated our computational proteochemometric systems network pharmacology platform, DrugGenEx-Net, with primary, continuous cultures of conditionally reprogrammed (CR) normal and prostate cancer (PCa) cells derived from treatment-naive patients with primary PCa. RESULTS Using the transcriptomic data from two matched pairs of benign and tumor-derived CR cells, we constructed drug networks to describe the biological perturbation associated with each prostate cell subtype at multiple levels of biological action. We prioritized the drugs by analyzing these networks for statistical coincidence with the drug action networks originating from known and predicted drug-protein targets. Prioritized drugs shared between the two patients' PCa cells included carfilzomib (CFZ), bortezomib (BTZ), sulforaphane, and phenethyl isothiocyanate. The effects of these compounds were then tested in the CR cells, in vitro. We observed that the IC50 values of the normal PCa CR cells for CFZ and BTZ were higher than their matched tumor CR cells. Transcriptomic analysis of CFZ-treated CR cells revealed that genes involved in cell proliferation, proteases, and downstream targets of serine proteases were inhibited while KLK7 and KLK8 were induced in the tumor-derived CR cells. CONCLUSIONS Given that the drugs in the database are extremely well-characterized and that the patient-derived cells are easily scalable for high throughput drug screening, this combined in vitro and in silico approach may significantly advance personalized PCa treatment and for other cancer applications.
Collapse
Affiliation(s)
- Aisha Naeem
- Department of Oncology, Lombardi Comprehensive Cancer CenterGeorgetown University Medical CenterWashington DC
- Ministry of Public HealthDohaQatar
| | - Sivanesan Dakshanamurthy
- Department of Oncology, Lombardi Comprehensive Cancer CenterGeorgetown University Medical CenterWashington DC
| | - Henry Walthieu
- Department of Oncology, Lombardi Comprehensive Cancer CenterGeorgetown University Medical CenterWashington DC
| | - Erika Parasido
- Department of Oncology, Lombardi Comprehensive Cancer CenterGeorgetown University Medical CenterWashington DC
| | - Maria Avantaggiati
- Department of Oncology, Lombardi Comprehensive Cancer CenterGeorgetown University Medical CenterWashington DC
| | - Lucas Tricoli
- Julius L. Chambers Biomedical/Biotechnology Research InstituteNorth Carolina Central UniversityDurhamNorth Carolina
| | - Deepak Kumar
- Julius L. Chambers Biomedical/Biotechnology Research InstituteNorth Carolina Central UniversityDurhamNorth Carolina
| | - Richard J. Lee
- Department of MedicineMassachusetts General Hospital Cancer CenterBostonMassachusetts
| | - Adam Feldman
- Department of MedicineMassachusetts General Hospital Cancer CenterBostonMassachusetts
| | | | - Stephen Byers
- Department of Oncology, Lombardi Comprehensive Cancer CenterGeorgetown University Medical CenterWashington DC
| | - Olga Rodriguez
- Department of Oncology, Lombardi Comprehensive Cancer CenterGeorgetown University Medical CenterWashington DC
- Center for Translational ImagingGeorgetown University Medical CenterWashington DC
| | - Chris Albanese
- Department of Oncology, Lombardi Comprehensive Cancer CenterGeorgetown University Medical CenterWashington DC
- Center for Translational ImagingGeorgetown University Medical CenterWashington DC
| |
Collapse
|
25
|
Demby TC, Rodriguez O, McCarthy CW, Lee YC, Albanese C, Mandelblatt J, Rebeck GW. A mouse model of chemotherapy-related cognitive impairments integrating the risk factors of aging and APOE4 genotype. Behav Brain Res 2020; 384:112534. [PMID: 32027870 PMCID: PMC7082850 DOI: 10.1016/j.bbr.2020.112534] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2019] [Revised: 01/22/2020] [Accepted: 02/01/2020] [Indexed: 01/05/2023]
Abstract
Some cancer survivors experience marked cognitive impairment, referred to as cancer-related cognitive impairment (CRCI). CRCI has been linked to the genetic factor APOE4, the strongest genetic risk factor for Alzheimer's disease (AD). We used APOE knock-in mice to test whether the relationship between APOE4 and CRCI can be demonstrated in a mouse model, to identify associations of chemotherapy with behavioural and structural correlates of cognition, and to test whether chemotherapy affects markers of AD. Twelve-month old C57BL/6 J female APOE3 (n = 30) and APOE4 (n = 31) knock-in mice were randomized to treatment with either doxorubicin (10 mg/kg) or saline. Behavioural assays at 2-21 weeks-post exposure included open field maze, elevated zero maze, pre-pulse inhibition, Barnes maze, and fear conditioning. Ex-vivo magnetic resonance imaging was used to determine regional volume differences at 31-35 weeks-post exposure, and tissue sections were analyzed for markers of AD pathogenesis. Minimal toxicities were observed in the aged mice after doxorubicin exposure. In the Barnes maze assay, APOE3 mice did not exhibit impairment in spatial learning after doxorubicin treatment, but APOE4 mice demonstrated significant impairments in both the initial identification of the escape hole and the latency to full escape at 6 weeks post-exposure. Both APOE3 and APOE4 mice treated with doxorubicin showed impairment of spatial memory. Grey matter volume in the frontal cortex decreased in APOE4 mice treated with doxorubicin vs. APOE3 mice. This study demonstrates cognitive impairments in aged APOE4 knock-in mice after doxorubicin treatment and establishes this system as a novel and powerful model of CRCI.
Collapse
Affiliation(s)
- Tamar C Demby
- Tumor Biology Program, Georgetown University Medical Center, Washington DC United States
| | - Olga Rodriguez
- Department of Oncology, Molecular Oncology Program, Georgetown University Medical Center, Washington DC United States; Center for Translational Imaging, Georgetown University Medical Center, Washington DC, United States
| | - Camryn W McCarthy
- Department of Neuroscience, Georgetown University Medical Center, Washington DC United States
| | - Yi-Chien Lee
- Department of Oncology, Molecular Oncology Program, Georgetown University Medical Center, Washington DC United States; Center for Translational Imaging, Georgetown University Medical Center, Washington DC, United States
| | - Christopher Albanese
- Department of Oncology, Molecular Oncology Program, Georgetown University Medical Center, Washington DC United States; Center for Translational Imaging, Georgetown University Medical Center, Washington DC, United States
| | - Jeanne Mandelblatt
- Department of Oncology, Cancer Prevention and Control Program, Georgetown University Medical Center, Washington DC, United States
| | - G William Rebeck
- Department of Neuroscience, Georgetown University Medical Center, Washington DC United States.
| |
Collapse
|
26
|
Ihemelandu C, Naeem A, Parasido E, Berry D, Chaldekas K, Harris BT, Rodriguez O, Albanese C. Clinicopathologic and prognostic significance of LGR5, a cancer stem cell marker in patients with colorectal cancer. Colorectal Cancer 2019; 8:CRC11. [PMID: 32038737 PMCID: PMC7000925 DOI: 10.2217/crc-2019-0009] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Aim: To analyze the clinicopathologic and prognostic significance of Leucine-rich repeat-containing G-protein-coupled receptor 5 (LGR5), a cancer stem cell marker expression in a cohort of colorectal cancer patients (CRC). Patients & methods: A total of 76 formalin-fixed paraffin-embedded tissue blocks of primary or metastatic tumors from 49 CRC patients were collected for duration 2009–2015. LGR5 expression was assessed through immunohistochemical staining of a tissue microarray. Results: LGR5 was significantly over expressed in CRC tissue samples and found to be a statistically significant independent prognostic marker for an improved overall survival. Conclusion: LGR5 expression was higher in colorectal cancer than in normal tissue. LGR5 was an independent prognostic marker for better clinical outcomes and might be used as a potential therapeutic target in CRCs.
Collapse
Affiliation(s)
- Chukwuemeka Ihemelandu
- Program in Peritoneal Surface Oncology, MedStar Surgical Oncology, Department of Surgery, MedStar Georgetown University Hospital, 3800 Reservoir Rd, NW Washington, DC 20007, USA.,Preclinical Imaging Research Laboratory, Center for Cell Reprogramming, Department of Oncology and Pathology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, 3800 Reservoir Rd, NW Washington, DC 20007, USA
| | - Aisha Naeem
- Preclinical Imaging Research Laboratory, Center for Cell Reprogramming, Department of Oncology and Pathology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, 3800 Reservoir Rd, NW Washington, DC 20007, USA.,Biostatistician, Preclinical imaging Research Laboratory, Department of Oncology and Pathology, Lombardi Comprehensive Cancer Center, Georgetown University Medical center, 3800 Reservoir Rd, NW Washington, DC 20007, USA
| | - Erika Parasido
- Preclinical Imaging Research Laboratory, Center for Cell Reprogramming, Department of Oncology and Pathology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, 3800 Reservoir Rd, NW Washington, DC 20007, USA
| | - Deborah Berry
- Histopathology & Tissue Shared Resource, Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, 3900 Reservoir Rd, Washington, DC 20007, USA.,Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center
| | - Krysta Chaldekas
- Histopathology & Tissue Shared Resource, Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, 3900 Reservoir Rd, Washington, DC 20007, USA.,Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center
| | - Brent T Harris
- Histopathology & Tissue Shared Resource, Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, 3900 Reservoir Rd, Washington, DC 20007, USA.,Departments of Neurology & Pathology, Georgetown University Medical Center
| | - Olga Rodriguez
- Preclinical Imaging Research Laboratory, Center for Cell Reprogramming, Department of Oncology and Pathology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, 3800 Reservoir Rd, NW Washington, DC 20007, USA.,Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center
| | - Christopher Albanese
- Preclinical Imaging Research Laboratory, Center for Cell Reprogramming, Department of Oncology and Pathology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, 3800 Reservoir Rd, NW Washington, DC 20007, USA.,Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center
| |
Collapse
|
27
|
Bos Real L, Vilades D, Jimenez M, Altisent O, Rodriguez O, Alomar X, Ferrero A, Schuijf J, Carreras F, Leta R. P6174On-site CT-derived FFR predicts the need for revascularization. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz746.0780] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background and purpose
Coronary computed tomography angiography (CTA) in combination with CT-derived fractional flow reserve (CT-FFR) is a solid tool for assessing both the anatomical and functional impact of coronary atherosclerotic disease (CAD) in a single study. The development of new software for on-site CT-FFR quantification may reduce costs and increase availability. The aim of this study was to analyze the incremental value of CT-FFR over CTA alone and its ability to predict the need for revascularization.
Methods
Patients referred for invasive coronary angiography (ICA) who accepted to undergo a CTA/CT-FFR study were prospectively included. Patients with any contraindication for CT, atrial fibrillation, chronic total occlusions, severe ventricular hypertrophy or previous coronary revascularization were excluded. On-site CT-FFR was calculated for each coronary vessel. Invasive FFR was quantified during ICA, considering ≤0.8 as a surrogate for the need for revascularization.
Results
33 patients (90 vessels) were included. Mean age was 65±10 years, 88% were males, 60% had hypertension, 77% dyslipidaemia and 40% diabetes. The average analysis time of CT-FFR was 16±4 minutes. There was a good correlation between CT-FFR and FFR in all three main epicardial vessels as well as in proximal segments or in moderate to severe stenosis (see Table). 83% of vessels with FFR≤0.8 were predicted by CT-FFR study (89% of LAD lesions, 86% of LCX and 66% of RCA). CT-FFR added incremental diagnostic value over CTA alone to predict FFR≤0.8 (ΔAUC 0.0336 with a net reclassification index 1.4±0.23; p<0.001) (see Image).
n Mean difference from Bland-Altman Pearson's r coefficient p value All-vessels 90 0.037±0.1 0.8 <0.001 Lesions in LAD 40 0.005±0.11 0.81 <0.001 Lesions in LCX 32 0.061±0.094 0.85 <0.001 Lesions in RCA 18 0.06±0.11 0.83 <0.001 Moderate lesions (50–69% QCA stenosis) 24 0.02±0.06 0.88 <0.001 Severe lesions (70–99% QCA stenosis) 25 0.034±0.18 0.4 <0.001 Proximal lesions 42 0.012±0.11 0.84 <0.001 Non-proximal lesions 48 0.061±0.1 0.78 <0.001
Conclusions
On-site CT-FFR is a good predictor of the need for revascularization in all three main coronary vessels and adds incremental diagnostic value over CTA alone. There is higher dispersion of the values in severe stenosis, lesions in LCX or RCA although this do not result in misclassification.
Collapse
Affiliation(s)
- L Bos Real
- Hospital de la Santa Creu i Sant Pau, Cardiac Imaging Unit, Barcelona, Spain
| | - D Vilades
- Hospital de la Santa Creu i Sant Pau, Cardiac Imaging Unit, Barcelona, Spain
| | - M Jimenez
- Hospital de la Santa Creu i Sant Pau, Interventional Cardiology, Barcelona, Spain
| | - O Altisent
- Germans Trias i Pujol Hospital, Interventional Cardiology, Badalona (Barcelona), Spain
| | - O Rodriguez
- Germans Trias i Pujol Hospital, Interventional Cardiology, Badalona (Barcelona), Spain
| | - X Alomar
- Clínica Creu Blanca, Barcelona, Spain
| | - A Ferrero
- Hospital de la Santa Creu i Sant Pau, Statistics and Research, Barcelona, Spain
| | - J Schuijf
- Global Research & Development Center, Canon Medical Systems Europe B.V., Zoetermeer, Netherlands (The)
| | - F Carreras
- Hospital de la Santa Creu i Sant Pau, Cardiac Imaging Unit, Barcelona, Spain
| | - R Leta
- Hospital de la Santa Creu i Sant Pau, Cardiac Imaging Unit, Barcelona, Spain
| |
Collapse
|
28
|
Bos Real L, Vilades D, Jimenez M, Altisent O, Rodriguez O, Alomar X, Ferrero A, Schuijf J, Carreras F, Leta R. P6185Impact of coronary atherosclerotic plaque metrics on the correlation between on-site CT-FFR and invasive FFR. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz746.0791] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Developed in the last years, coronary computed tomography-derived fractional flow reserve (CT-FFR) has shown good correlation with invasive fractional flow reserve (FFR). However, little is known about the interaction of coronary atherosclerotic plaque characteristics in the correlation between CT-FFR and FFR.
Purpose
This study sought to determine the effect of main coronary atherosclerotic plaque metrics (APM) on the correlation between on-site CT-FFR and invasive FFR.
Methods
Patients referred for invasive coronary angiography (ICA) who accepted to undergo a CT-FFR study were prospectively included. We excluded patients with atrial fibrillation, chronic total occlusions, severe ventricular hypertrophy or previous coronary revascularization, and those with any contraindication for CT. On-site CT-FFR and APM were calculated for each coronary vessel. Continuous variables of APM were dichotomized as above and below the median and their interaction on the correlation between on-site CT-FFR and invasive FFR was assessed by multiple linear regression model.
Results
33 patients (90 vessels) were included. Mean age was 65±10 years, 88% were males, 60% had hypertension, 77% dyslipidaemia and 40% diabetes. The mean delay time between CTA and ICA of 21 days. The average analysis time of CT-FFR was 16±4 minutes. Overall, correlation between FFR and CT-FFR showed a Pearson's r coefficient of 0.77±0.06 and a standardized beta coefficient of 0.8 (p<0.001). The beta coefficients between CT-FFR and FFR did not change significantly after the interaction with different APM (p>0.05 for all) (see Table).
Standardized Beta coefficients for on-site CT-FFR with invasive FFR as a gold standard Below the median Above the median p value for interaction Total atheroma volume (TAV) (mm3) 0.66 0.93 0.071 Percent atheroma volume (PAV) (%) 1.00 0.69 0.063 Calcified atheroma plaque volume (%) 0.89 0.68 0.175 Remodeling index 0.94 0.71 0.129 Lesion length (LL) (mm) 0.67 0.89 0.158 Minimal lumen area (mm2) 0.73 0.71 0.955
Conclusions
There is a good correlation between on-site CT-FFR and invasive FFR, which is not affected by main atherosclerotic plaque characteristics.
Collapse
Affiliation(s)
- L Bos Real
- Hospital de la Santa Creu i Sant Pau, Cardiac Imaging Unit, Barcelona, Spain
| | - D Vilades
- Hospital de la Santa Creu i Sant Pau, Cardiac Imaging Unit, Barcelona, Spain
| | - M Jimenez
- Hospital de la Santa Creu i Sant Pau, Interventional Cardiology, Barcelona, Spain
| | - O Altisent
- Germans Trias i Pujol Hospital, Interventional Cardiology, Badalona (Barcelona), Spain
| | - O Rodriguez
- Germans Trias i Pujol Hospital, Interventional Cardiology, Badalona (Barcelona), Spain
| | - X Alomar
- Clínica Creu Blanca, Barcelona, Spain
| | - A Ferrero
- Hospital de la Santa Creu i Sant Pau, Statistics and Research, Barcelona, Spain
| | - J Schuijf
- Global Research & Development Center, Canon Medical Systems Europe B.V., Zoetermeer, Netherlands (The)
| | - F Carreras
- Hospital de la Santa Creu i Sant Pau, Cardiac Imaging Unit, Barcelona, Spain
| | - R Leta
- Hospital de la Santa Creu i Sant Pau, Cardiac Imaging Unit, Barcelona, Spain
| |
Collapse
|
29
|
Parasido E, Avetian GS, Naeem A, Graham G, Pishvaian M, Glasgow E, Mudambi S, Lee Y, Ihemelandu C, Choudhry M, Peran I, Banerjee PP, Avantaggiati ML, Bryant K, Baldelli E, Pierobon M, Liotta L, Petricoin E, Fricke ST, Sebastian A, Cozzitorto J, Loots GG, Kumar D, Byers S, Londin E, DiFeo A, Narla G, Winter J, Brody JR, Rodriguez O, Albanese C. The Sustained Induction of c-MYC Drives Nab-Paclitaxel Resistance in Primary Pancreatic Ductal Carcinoma Cells. Mol Cancer Res 2019; 17:1815-1827. [PMID: 31164413 PMCID: PMC6726538 DOI: 10.1158/1541-7786.mcr-19-0191] [Citation(s) in RCA: 36] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2019] [Revised: 04/18/2019] [Accepted: 05/31/2019] [Indexed: 12/18/2022]
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive disease with limited and, very often, ineffective medical and surgical therapeutic options. The treatment of patients with advanced unresectable PDAC is restricted to systemic chemotherapy, a therapeutic intervention to which most eventually develop resistance. Recently, nab-paclitaxel (n-PTX) has been added to the arsenal of first-line therapies, and the combination of gemcitabine and n-PTX has modestly prolonged median overall survival. However, patients almost invariably succumb to the disease, and little is known about the mechanisms underlying n-PTX resistance. Using the conditionally reprogrammed (CR) cell approach, we established and verified continuously growing cell cultures from treatment-naïve patients with PDAC. To study the mechanisms of primary drug resistance, nab-paclitaxel-resistant (n-PTX-R) cells were generated from primary cultures and drug resistance was verified in vivo, both in zebrafish and in athymic nude mouse xenograft models. Molecular analyses identified the sustained induction of c-MYC in the n-PTX-R cells. Depletion of c-MYC restored n-PTX sensitivity, as did treatment with either the MEK inhibitor, trametinib, or a small-molecule activator of protein phosphatase 2a. IMPLICATIONS: The strategies we have devised, including the patient-derived primary cells and the unique, drug-resistant isogenic cells, are rapid and easily applied in vitro and in vivo platforms to better understand the mechanisms of drug resistance and for defining effective therapeutic options on a patient by patient basis.
Collapse
Affiliation(s)
- Erika Parasido
- Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, D.C
| | - George S Avetian
- Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, D.C
| | - Aisha Naeem
- Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, D.C
| | - Garrett Graham
- Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, D.C
| | - Michael Pishvaian
- Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, D.C
| | - Eric Glasgow
- Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, D.C
| | - Shaila Mudambi
- Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, D.C
| | - Yichien Lee
- Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, D.C
| | - Chukwuemeka Ihemelandu
- Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, D.C
| | - Muhammad Choudhry
- Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, D.C
| | - Ivana Peran
- Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, D.C
| | - Partha P Banerjee
- Department of Biochemistry, Molecular and Cell Biology, Georgetown University Medical Center, Washington, D.C
| | - Maria Laura Avantaggiati
- Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, D.C
| | - Kirsten Bryant
- Department of Pharmacology, University of North Carolina, Chapel Hill, Chapel Hill, North Carolina
| | - Elisa Baldelli
- Center for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, Virginia
| | - Mariaelena Pierobon
- Center for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, Virginia
| | - Lance Liotta
- Center for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, Virginia
| | - Emanuel Petricoin
- Center for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, Virginia
| | - Stanley T Fricke
- Center for Translational Imaging, Georgetown University Medical Center, Washington, D.C
| | - Aimy Sebastian
- Biology and Biotechnology Division, Lawrence Livermore National Laboratory, Livermore, California
| | - Joseph Cozzitorto
- Division of Surgical Research, Department of Surgery, Jefferson Pancreas, Biliary and Related Cancer Center, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania
| | - Gabriela G Loots
- Biology and Biotechnology Division, Lawrence Livermore National Laboratory, Livermore, California
| | - Deepak Kumar
- Department of Pharmaceutical Sciences, Julius L. Chambers Biomedical/Biotechnology Research Institute (JLC-BBRI), North Carolina Central University, Durham, North Carolina
| | - Stephen Byers
- Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, D.C
| | - Eric Londin
- Computational Medicine Center, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania
| | - Analisa DiFeo
- Division of Genetic Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan
| | - Goutham Narla
- Division of Genetic Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan
| | - Jordan Winter
- Division of Surgical Research, Department of Surgery, Jefferson Pancreas, Biliary and Related Cancer Center, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania
- Case Western Reserve School of Medicine, Case Comprehensive Cancer Center and University Hospitals Cleveland Medical Center, Cleveland, Ohio
| | - Jonathan R Brody
- Division of Surgical Research, Department of Surgery, Jefferson Pancreas, Biliary and Related Cancer Center, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania
| | - Olga Rodriguez
- Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, D.C
- Center for Translational Imaging, Georgetown University Medical Center, Washington, D.C
| | - Chris Albanese
- Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, D.C.
- Center for Translational Imaging, Georgetown University Medical Center, Washington, D.C
| |
Collapse
|
30
|
Demby TC, Lee Y, Rodriguez O, Albanese C, Mandelblatt J, Rebeck GW. Abstract 667: A mouse model of APOE to define effects of doxorubicin on cognition. Cancer Res 2019. [DOI: 10.1158/1538-7445.am2019-667] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
The purpose of this study was to establish the effects of Apolipoprotein E (APOE) genotype on cognitive function following doxorubicin treatment in a mouse model. Chemotherapy treatment can lead to cognitive impairment in cancer survivors, and, in older breast cancer survivors, APOE4 carriers have been shown to have higher risk for these impairments. Though APOE4 genotype is known as the strongest genetic risk factor for late-onset Alzheimer’s Disease compared to the APOE2 and APOE3 alleles, its effects on cognitive outcomes following treatment with common breast cancer chemotherapeutics are not yet well characterized. One year old female mice with targeted replacement of human APOE3 or APOE4 under control of the endogenous murine promoter were treated with 10 mg/kg doxorubicin or saline. Five weeks following treatment, spatial learning and memory was tested using the Barnes Maze. In APOE3 mice, doxorubicin treatment left spatial learning and memory intact. In APOE4 mice, doxorubicin treatment lead to impairment in spatial learning over the four days of training. This represents a promising model for studying the mechanisms behind cognitive impairment following doxorubicin treatment in a genetically vulnerable population.
Citation Format: Tamar C. Demby, Yichien Lee, Olga Rodriguez, Christopher Albanese, Jeanne Mandelblatt, G. William Rebeck. A mouse model of APOE to define effects of doxorubicin on cognition [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 667.
Collapse
|
31
|
Dahanayake V, Pornrungroj C, Pablico-Lansigan M, Hickling WJ, Lyons T, Lah D, Lee Y, Parasido E, Bertke JA, Albanese C, Rodriguez O, Van Keuren E, Stoll SL. Paramagnetic Clusters of Mn 3(O 2CCH 3) 6(Bpy) 2 in Polyacrylamide Nanobeads as a New Design Approach to a T 1- T 2 Multimodal Magnetic Resonance Imaging Contrast Agent. ACS Appl Mater Interfaces 2019; 11:18153-18164. [PMID: 30964631 PMCID: PMC8515904 DOI: 10.1021/acsami.9b03216] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/05/2023]
Abstract
There is an increasing need for gadolinium-free magnetic resonance imaging (MRI) contrast agents, particularly for patients suffering from chronic kidney disease. Using a cluster-nanocarrier combination, we have identified a novel approach to the design of biomedical nanomaterials and report here the criteria for the cluster and the nanocarrier and the advantages of this combination. We have investigated the relaxivity of the following manganese oxo clusters: the parent cluster Mn3(O2CCH3)6(Bpy)2 (1) where Bpy = 2,2'-bipyridine and three new analogs, Mn3(O2CC6H4CH═CH2)6(Bpy)2 (2), Mn3(O2CC(CH3)═CH2)6(Bpy)2 (3), and Mn3O(O2CCH3)6(Pyr)2 (4) where Pyr = pyridine. The parent cluster, Mn3(O2CCH3)6(Bpy)2 (1), had impressive relaxivity ( r1 = 6.9 mM-1 s-1, r2 = 125 mM-1 s-1) and was found to be the most amenable for the synthesis of cluster-nanocarrier nanobeads. Using the inverse miniemulsion polymerization technique (1) in combination with the hydrophilic monomer acrylamide, we synthesized nanobeads (∼125 nm diameter) with homogeneously dispersed clusters within the polyacrylamide matrix (termed Mn3Bpy-PAm). The nanobeads were surface-modified by co-polymerization with an amine-functionalized monomer. This enabled various postsynthetic modifications, for example, to attach a near-IR dye, Cyanine7, as well as a targeting agent. When evaluated as a potential multimodal MRI contrast agent, high relaxivity and contrast were observed with r1 = 54.4 mM-1 s-1 and r2 = 144 mM-1 s-1, surpassing T1 relaxivity of clinically used Gd-DTPA chelates as well as comparable T2 relaxivity to iron oxide microspheres. Physicochemical properties, cellular uptake, and impacts on cell viability were also investigated.
Collapse
Affiliation(s)
- Vidumin Dahanayake
- Department of Chemistry, Institute for Soft Matter Synthesis and Metrology, Georgetown University, 37th and O Streets NW, Washington, DC 20057, United States
| | - Chanon Pornrungroj
- Department of Physics, Institute for Soft Matter Synthesis and Metrology, Georgetown University, 37th and O Streets NW, Washington, DC 20057, United States
- IMRAM, Tohoku University, 2-1-1 Katahira, Aoba-ku, Sendai 980-8577, Japan
| | - Michele Pablico-Lansigan
- Department of Chemistry, American University, 4400 Massachusetts Avenue, NW, Washington, DC 20016, United States
| | - William J. Hickling
- Department of Chemistry, Institute for Soft Matter Synthesis and Metrology, Georgetown University, 37th and O Streets NW, Washington, DC 20057, United States
| | - Trevor Lyons
- Department of Chemistry, Institute for Soft Matter Synthesis and Metrology, Georgetown University, 37th and O Streets NW, Washington, DC 20057, United States
| | - David Lah
- Department of Chemistry, Institute for Soft Matter Synthesis and Metrology, Georgetown University, 37th and O Streets NW, Washington, DC 20057, United States
| | - Yichien Lee
- Department of Oncology, Lombardi Comprehensive Cancer Center and Center for Translational Imaging, Georgetown University Medical Center, Washington, DC 20057, United States
| | - Erika Parasido
- Department of Oncology, Lombardi Comprehensive Cancer Center and Center for Translational Imaging, Georgetown University Medical Center, Washington, DC 20057, United States
| | - Jeffery A. Bertke
- Department of Chemistry, Institute for Soft Matter Synthesis and Metrology, Georgetown University, 37th and O Streets NW, Washington, DC 20057, United States
| | - Christopher Albanese
- Department of Oncology, Lombardi Comprehensive Cancer Center and Center for Translational Imaging, Georgetown University Medical Center, Washington, DC 20057, United States
| | - Olga Rodriguez
- Department of Oncology, Lombardi Comprehensive Cancer Center and Center for Translational Imaging, Georgetown University Medical Center, Washington, DC 20057, United States
| | - Edward Van Keuren
- Department of Physics, Institute for Soft Matter Synthesis and Metrology, Georgetown University, 37th and O Streets NW, Washington, DC 20057, United States
| | - Sarah L. Stoll
- Department of Chemistry, Institute for Soft Matter Synthesis and Metrology, Georgetown University, 37th and O Streets NW, Washington, DC 20057, United States
- Corresponding Author:
| |
Collapse
|
32
|
Galli S, Hong SH, Tilan JU, Adnani M, Zhu S, Fallah Y, Lee YC, Rodriguez O, Albanese C, Izycka-Swieszewska E, Kitlinska J. Abstract B13: Perineural invasion in Ewing sarcoma—a novel mechanism and new therapeutic opportunities. Cancer Res 2018. [DOI: 10.1158/1538-7445.pedca17-b13] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Tumor dissemination and relapse are the major problems in Ewing sarcoma (ES) treatment, yet the mechanisms driving these processes are unknown. To elucidate the routes of ES metastatic spread, we used an orthotopic xenograft model. ES cells were injected into the gastrocnemius muscles of SCID/beige mice. Once the primary tumors reached the desired volume, they were excised by limb amputation. Subsequently, tumor dissemination was monitored by MRI and confirmed by histopathologic analysis. Interestingly, aside from typical hematogenous metastases, such as bone and lung lesions, we have also observed frequent perineural tumor dissemination manifested by the presence of migratory ES cells along the nerves adjacent to the primary tumors. This phenomenon was associated with formation of recurrent tumors at the amputation sites, as well as pelvic tumors with spine involvement. Interestingly, the level of perineural invasion (PNI) was dependent on the expression of neuropeptide Y (NPY) in ES cells. NPY is a neuronal protein released from peripheral sympathetic neurons, but also highly expressed in ES cells along with its receptors. The xenografts derived from ES cell lines not releasing endogenous NPY (TC71, TC32) exhibited frequent PNI in tumor-bearing limbs, as well as a high number of recurrent tumors at the surgery site and spine metastases (70% and 100% of mice with evidence of PNI for TC71 and TC32 xenografts, respectively). This phenomenon was less common in ES xenografts derived from NPY-rich SK-ES1 cells (17% of mice with signs of PNI). In line with these observations, NPY knockdown in SK-ES1 xenografts drastically accelerated formation of spinal tumors (60% of mice). Notably, in 40% of mice bearing SK-ES1/NPY shRNA xenografts the spinal tumors developed before the primary tumor growth was detectable at the site of ES cell injection. Thus, our in vivo experiments suggested that a lack of endogenous NPY in ES cells expressing high levels of its receptors triggers chemotactic effects of this peptide released from neighboring peripheral nerves, facilitating PNI. Indeed, in a transwell migration assay, NPY exerted significant chemotactic activity in SK-ES1/NPY shRNA cells, but not in the original SK-ES1 cell line. An even more profound chemotactic effect specific to the SK-ES1/NPY shRNA cells was observed with NPY-rich conditioned media obtained from neuroblastoma cells, which can serve as a model of peripheral sympathetic neurons. Further studies are required to determine which NPY receptors are responsible for its chemotactic properties. If the presence of perineural tumor growth is confirmed in human tumors, factors responsible for PNI in ES, e.g., NPY receptors, may become targets for novel therapies preventing disease dissemination and recurrence.
Citation Format: Susana Galli, Sung-Hyeok Hong, Jason U. Tilan, Mina Adnani, Shiya Zhu, Yassi Fallah, Yi-Chien Lee, Olga Rodriguez, Chris Albanese, Ewa Izycka-Swieszewska, Joanna Kitlinska. Perineural invasion in Ewing sarcoma—a novel mechanism and new therapeutic opportunities [abstract]. In: Proceedings of the AACR Special Conference: Pediatric Cancer Research: From Basic Science to the Clinic; 2017 Dec 3-6; Atlanta, Georgia. Philadelphia (PA): AACR; Cancer Res 2018;78(19 Suppl):Abstract nr B13.
Collapse
Affiliation(s)
| | | | | | | | - Shiya Zhu
- 1Georgetown University, Washington, DC,
| | | | | | | | | | | | | |
Collapse
|
33
|
Barbier L, Ramos E, Mendiola J, Rodriguez O, Santamaria G, Santamaria J, Arteagoitia I. Autologous dental pulp mesenchymal stem cells for inferior third molar post-extraction socket healing: A split-mouth randomised clinical trial. Med Oral Patol Oral Cir Bucal 2018; 23:e469-e477. [PMID: 29924768 PMCID: PMC6051678 DOI: 10.4317/medoral.22466] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2018] [Accepted: 06/15/2018] [Indexed: 01/04/2023] Open
Abstract
Background Since the discovery of adult mesenchymal stem cells extensive research has been conducted to determine their mechanisms of differentiation and effectiveness in cell therapy and regenerative medicine. Material and Methods To assess the efficacy of autologous dental pulp mesenchymal stem cells delivered in a collagen matrix for post-extraction socket healing, a single-centre, double-blind, randomised, split-mouth, controlled clinical trial was performed. Both impacted mandibular third molars were extracted from 32 patients. Dental pulp was collected and dissociated; the resulting cell suspension, obtained by centrifugation, was incorporated into a resorbable collagen matrix and implanted in 32 experimental post-extraction sockets. Collagen matrices alone were implanted in 32 contralateral, control post-extraction sockets. Two neuroradiologists independently assessed the extent of bone repair at 6 months after the extractions. Computed tomography (CT, Philips Brilliance) and an advanced display platform (IntelliSpace Portal) was used to record extraction socket density, expressed as Hounsfield units (HU) and height (mm) of the distal interdental bone septum of the second molar. Measurements at 6 months post-extraction were compared with measurements obtained immediately after extraction. Data were analysed with the statistical program STATA 14. Results Two patients dropped out of the study. The final sample consisted of 22 women and 8 men (mean age, 23 years; range: 18–30 years). Clinical, radiological, and surgical characteristics of impacted third molars of the control and experimental groups were homogeneous. Measurements obtained by the two neuroradiologists showed agreement. No significant differences were found in the extent of bone repair during analyses of density (p=0.4203 neuroradiologist 1; p=0.2525 neuroradiologist 2) or interdental septum height (p=0.2280 neuroradiologist 1; p=0.4784 neuroradiologist 2). Conclusions In our clinical trial, we were unable to demonstrate that autologous dental pulp mesenchymal stem cells reduce socket bone resorption after inferior third molar extraction. Key words:Clinical trial, autologous, pulpal stem cells, extraction socket healing.
Collapse
Affiliation(s)
- L Barbier
- University of Basque Country, Departamento de Estomatologia, c/ Barrio Sarriena s/n, 48940 Leioa, Bizkaia,
| | | | | | | | | | | | | |
Collapse
|
34
|
Palafox M, Herrera-Abreu MT, Bellet M, Oliveira M, Bruna A, Rodriguez O, Guzmán M, Grueso J, Vilaplana C, Arribas J, Tomaso ED, Su F, Caldas C, Turner NC, Dienstmann R, Baselga J, Scaltriti M, Cortés J, Saura C, Serra V. Abstract 3596: Biomarkers of response to CDK4/6 inhibitor (CDK4/6i) in hormone receptor (HR) positive and HER2-positive breast cancer (BC) patient-derived xenografts (PDX). Cancer Res 2018. [DOI: 10.1158/1538-7445.am2018-3596] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
The cell cycle G1-restriction point is frequently deregulated in HR+ BC by alterations of cyclin D1 (CCND1), p16 (CDKN2A) or pRb (RB1). CDK4/6i (ribociclib, abemaciclib and palbociclib) have shown clinical activity in metastatic HR+ BC, both as single agents and in combination with endocrine therapy. Currently, no biomarkers of response to CDK4/6i have been identified beyond HR expression and little is known about mechanisms of acquired resistance.
Twenty-one PDXs were established from HR+, HER2+ or HR+/HER2+ BC patient biopsies and their response to ribociclib was evaluated in vivo and ex vivo in matrigel cultures. Acquired-resistance was generated in vivo by isolating tumors that escaped therapy overtime. In order to identify response biomarkers, genetic and proteomic analysis of PDXs were performed and correlated with ribociclib antitumor activity. Candidates were validated in a cohort of 8 tumor samples from patients treated with abemaciclib monotherapy and in vitro. Combination with the PI3K-alpha inhibitor (PI3Ki) BYL719 was explored in vivo.
In vivo, ribociclib exhibited antitumor activity in five out of 21 PDXs (24%), two of which acquired resistance after continuous dosage (75mg/kg, 6IW). Ex vivo matrigel cultures recapitulated the in vivo response with 75% sensitivity and 92% specificity (p=0.01), providing a novel approach for high throughput screening. Baseline levels of ER, PR and Ki67 protein or PIK3CA/ESR1 mutations did not discriminate between ribociclib-resistant/sensitive PDXs, whereas CCND1/D2-amplification/overexpression were only found in ribociclib-resistant models. Importantly, sensitive PDXs exhibited significant Ki67 reduction upon ribociclib treatment, higher baseline pRb- and lower p16-staining compared to ribociclib-resistant PDXs (p=0.004, 0.02 and 0.03, respectively). Three out of 8 acquired-resistant tumors (37.5%) exhibited pRb loss. In vitro, RB1 knockdown and cyclin D1/D2-overexpression resulted in higher BrdU incorporation and higher IC50 than control cells upon ribociclib treatment. p16 expression was significantly lower in samples of patients exhibiting clinical benefit with abemaciclib monotherapy (p=0.04). Remarkably, combination of ribociclib with a PI3Ki resulted in appreciable antitumor activity in 18 out of 20 PDXs (90%), including two models resistant to fulvestrant given in combination with ribociclib.
In conclusion, HR+, HER2+ and HR+/HER2+ BC PDXs expressing both high Rb- and low p16-protein levels are sensitive to CDK4/6i whereas deregulation of the G1-restriction point due to low pRb or high cyclin D1/D2 protein levels is associated with resistance to ribociclib monotherapy. Addition of a PI3Ki markedly improves the antitumor response of ribociclib in most of PDXs, suggesting that the PI3K pathway may play a pivotal role in limiting the efficacy of CDK4/6 inhibition.
Citation Format: Marta Palafox, María Teresa Herrera-Abreu, Meritxell Bellet, Mafalda Oliveira, Alejandra Bruna, Olga Rodriguez, Marta Guzmán, Judit Grueso, Cristina Vilaplana, Joaquín Arribas, Emmanuelle di Tomaso, Faye Su, Carlos Caldas, Nicholas C. Turner, Rodrigo Dienstmann, José Baselga, Maurizio Scaltriti, Javier Cortés, Cristina Saura, Violeta Serra. Biomarkers of response to CDK4/6 inhibitor (CDK4/6i) in hormone receptor (HR) positive and HER2-positive breast cancer (BC) patient-derived xenografts (PDX) [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 3596.
Collapse
Affiliation(s)
- Marta Palafox
- 1Vall D´Hebron Institute of Oncology, Barcelona, Spain
| | | | | | | | | | | | - Marta Guzmán
- 1Vall D´Hebron Institute of Oncology, Barcelona, Spain
| | - Judit Grueso
- 1Vall D´Hebron Institute of Oncology, Barcelona, Spain
| | | | | | | | - Faye Su
- 4Novartis Pharmaceutical Corporation, Cambridge, United Kingdom
| | - Carlos Caldas
- 3CRUK Cambridge institute, Cambridge, United Kingdom
| | | | | | - José Baselga
- 6Memorial Sloan-Kettering Cancer Center, New York, NY
| | | | - Javier Cortés
- 1Vall D´Hebron Institute of Oncology, Barcelona, Spain
| | | | - Violeta Serra
- 1Vall D´Hebron Institute of Oncology, Barcelona, Spain
| |
Collapse
|
35
|
Tricoli L, Naeem A, Parasido E, Mikhaiel JP, Choudhry MU, Berry DL, Abdelgawad IA, Lee RJ, Feldman AS, Ihemelandu C, Avantaggiati M, Kumar D, Byers S, Gallagher R, Wulfkuhle J, Petricoin E, Rodriguez O, Albanese C. Characterization of the effects of defined, multidimensional culture conditions on conditionally reprogrammed primary human prostate cells. Oncotarget 2018; 9:2193-2207. [PMID: 29416764 PMCID: PMC5788632 DOI: 10.18632/oncotarget.23363] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2017] [Accepted: 11/02/2017] [Indexed: 12/29/2022] Open
Abstract
The inability to propagate human prostate epithelial cells indefinitely has historically presented a serious impediment to prostate cancer research. The conditionally reprogrammed cell (CRC) approach uses the combination of irradiated J2 mouse fibroblasts and a Rho kinase inhibitor such as Y27632 to support the continuous culture of cells derived from most epithelial tissues, including the prostate. Due to their rapid establishment and overall ease of use, CRCs are now widely used in a variety of basic and preclinical settings. In addition, CRCs were successfully used to clinically treat respiratory papillomatosis. Although both normal and tumor-derived prostate CRCs have been used to study the basic biology of prostate cancer and to test new therapies, certain limitations exist. We have previously reported that prostate CRCs form functional prostate glands when implanted under the mouse renal capsule. However in conventional culture, the prostate CRCs exist in an adult stem-like, transient amplifying state and consequently do not adequately recapitulate several important features of a differentiated prostate epithelium. To address these limitations, we previously described a transwell dish-based model that supported the culturing of prostate CRCs and the collection of cells and cell extracts for molecular and genetic analyses. Using normal and tumor-derived prostate CRCs, we describe the combined effects of the multi-dimensional transwell platform and defined culture media on prostate cellular proliferation, differentiation and signaling.
Collapse
Affiliation(s)
- Lucas Tricoli
- Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA
- Julius L. Chambers Biomedical/Biotechnology Research Institute, North Carolina Central University, Durham, NC, USA
| | - Aisha Naeem
- Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA
| | - Erika Parasido
- Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA
| | - John P. Mikhaiel
- Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA
| | - Muhammad Umer Choudhry
- Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA
| | - Deborah L. Berry
- Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA
| | | | - Richard J. Lee
- Massachusetts General Hospital Cancer Center, Boston, MA, USA
| | - Adam S. Feldman
- Massachusetts General Hospital Cancer Center, Boston, MA, USA
| | - Chukwuemeka Ihemelandu
- Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA
| | - Maria Avantaggiati
- Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA
| | - Deepak Kumar
- Julius L. Chambers Biomedical/Biotechnology Research Institute, North Carolina Central University, Durham, NC, USA
| | - Stephen Byers
- Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA
| | - Rosa Gallagher
- Center for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, VA, USA
| | - Julia Wulfkuhle
- Center for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, VA, USA
| | - Emanuel Petricoin
- Center for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, VA, USA
| | - Olga Rodriguez
- Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA
- Preclinical Imaging Research Laboratory, Georgetown University Medical Center, Washington, DC, USA
| | - Chris Albanese
- Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA
- Preclinical Imaging Research Laboratory, Georgetown University Medical Center, Washington, DC, USA
| |
Collapse
|
36
|
Tricoli LJ, Berry D, Parasido E, Naeem A, Rodriguez O, Abdelgawad I, Lee R, Feldman A, Albanese C. Abstract 4829: Development of rapid 3-dimensional culture conditions that support the in vitro differentiation of conditionally reprogrammed primary prostate cells for the study of prostate cancer. Cancer Res 2017. [DOI: 10.1158/1538-7445.am2017-4829] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Despite decades of research into the causes and possible cures, prostate cancer (PCa) remains the second leading cause of cancer related death in men with over 26,000 deaths each year in the United States alone. While many of the studies performed over the years have identified important genes and signaling pathways that are involved in prostate carcinogenesis, the fact remains that due to the limited and suboptimal prostate cell lines available for correlative analyses, significant unmet needs exist in validating clinical findings. With this realization, many agencies such as the DOD and the NIH are funding more rapid and clinically relevant patient derived models to fill a void in our understanding of, and our ability to treat, cancer.
Our research has been on the forefront in development of a novel approach to use patient samples for basic, preclinical and clinical applications, significantly advancing personalized medicine with a revolutionary new primary cell culture technique termed conditionally reprogrammed cells (CRCs). In fact, the CRC approach is a major focus area of NIH U01/PAR 16-344.
We have pioneered the CRC technology for the rapid establishment and expansion of patient-derived normal and cancerous prostate cell lines in typical tissue culture conditions. We hypothesize that improved in vitro and in vivo platforms using patient-derived prostate cells (e.g. CRCs) are required for the elucidation and subsequent experimental verification of key molecular and genetic drivers for PCa as well as better curative approaches.
While prostate CRCs retain their lineage commitment, they fail to express many of the differentiation markers associated with luminal prostate cells when grown under normal two dimensional (2D) culture conditions. We have therefore established three dimensional (3D) non-spheroid based platforms for differentiation of both normal and malignant prostate CRCs. These include both transwell-based systems and decellularized tissue matrices that use defined differentiation medias to enable AR activation and a luminal cell phenotype. We have now demonstrated the in vitro re-engagement of key determinates in the AR pathway and differentiation to luminal prostate cells.
Documentation of the proper engagement of AR signaling is a significant step in developing a more accurate and tractable model for prostate cancer research and distinguishing between indolent and aggressive disease.
Citation Format: Lucas James Tricoli, Deborah Berry, Erika Parasido, Aisha Naeem, Olga Rodriguez, Iman Abdelgawad, Richard Lee, Adam Feldman, Chris Albanese. Development of rapid 3-dimensional culture conditions that support the in vitro differentiation of conditionally reprogrammed primary prostate cells for the study of prostate cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 4829. doi:10.1158/1538-7445.AM2017-4829
Collapse
Affiliation(s)
| | - Deborah Berry
- 1Georgetown Lombardi Comprehensive Cancer Center, Washington, DC
| | - Erika Parasido
- 1Georgetown Lombardi Comprehensive Cancer Center, Washington, DC
| | - Aisha Naeem
- 1Georgetown Lombardi Comprehensive Cancer Center, Washington, DC
| | - Olga Rodriguez
- 1Georgetown Lombardi Comprehensive Cancer Center, Washington, DC
| | | | - Richard Lee
- 3Massachusetts General Hospital Cancer Center, Boston, MA
| | - Adam Feldman
- 3Massachusetts General Hospital Cancer Center, Boston, MA
| | - Chris Albanese
- 1Georgetown Lombardi Comprehensive Cancer Center, Washington, DC
| |
Collapse
|
37
|
Hong SH, Wietlisbach L, Galli S, Mahajan A, Zhu S, Tilan J, Lee Y, Rodriguez O, Albanese C, Kitlinska J. Abstract 1940: Prenatal stress increases malignancy of neuroblastoma tumors in TH-MYCN animal model. Cancer Res 2017. [DOI: 10.1158/1538-7445.am2017-1940] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Neuroblastoma (NB) is a pediatric malignancy arising due to defects in sympathetic neuron differentiation. NB is a heterogeneous disease, with phenotypes ranging from spontaneously regressing to highly aggressive, incurable tumors. This clinical variability cannot be explained solely by genetic aberrations. Even in families with hereditary NB the penetrance of the disease is incomplete and the same genetic mutation often results in tumors with phenotypes varying from differentiating ganglioneuromas to undifferentiated, highly aggressive NBs. Thus, other, perhaps non-genetic factors can contribute to the disease development and modify its phenotype. Strikingly, the two factors promoting de-differentiation of NB cells and their malignant phenotype, hypoxia and glucocorticoids, are elevated in the fetus during maternal stress, suggesting a role for prenatal stress in NB tumorigenesis. Previously, using TH-MYCN mice as a model of aggressive NB, we have shown that an increase in maternal corticosterone levels during pregnancy attained by inserting slow release pellets resulted in increased tumor frequency in TH-MYCN offspring. The goal of the current study was to determine the effect of prenatal stress on NB metastasis. To this end, pregnant mice carrying TH-MYCN hemizygous offspring were subjected to chronic stress at embryonic days 10-17, the time of sympathetic neuroblast proliferation and differentiation. Two established stress paradigms were used - chronic unpredictable stress, in which mice were subjected daily to various stressors, and chronic cold stress comprising of daily 30 min exposure to cold. The phenotypes of the disease and its dissemination were compared between offspring of control and stressed mothers. The offspring from both prenatally stressed groups presented with more malignant disease, as manifested by the presence of advanced lung metastases disseminating from small primary tumors (<200 mm3). This phenotype was associated with increased mortality in prenatally-stressed TH-MYCN offspring (p<0.01). In contrast, no advanced lung metastases and no disease-related deaths were observed in TH-MYCN offspring of control mothers despite the presence of large primary tumors (>1,000 mm3). Although not common, lung metastases occur preferentially in NB patients with MYCN amplification and are associated with significantly worse prognosis, as compared to patients with metastatic disease, but no pulmonary involvement (14 vs 43% 3-year event-free survival, respectively). Thus, the profound pulmonary dissemination observed in prenatally-stressed TH-MYCN mice mimics one of the most malignant NB phenotypes observed in human disease. Altogether, our data implicate maternal stress during pregnancy as a potential environmental factor modifying the effects of genetic aberrations and promoting malignant phenotype of NB.
Citation Format: Sung Hyeok Hong, Larissa Wietlisbach, Susana Galli, Akanksha Mahajan, Shiya Zhu, Jason Tilan, Yichien Lee, Olga Rodriguez, Chris Albanese, Joanna Kitlinska. Prenatal stress increases malignancy of neuroblastoma tumors in TH-MYCN animal model [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 1940. doi:10.1158/1538-7445.AM2017-1940
Collapse
Affiliation(s)
| | | | - Susana Galli
- Georgetown University Medical Center, Washington, DC
| | | | - Shiya Zhu
- Georgetown University Medical Center, Washington, DC
| | - Jason Tilan
- Georgetown University Medical Center, Washington, DC
| | - Yichien Lee
- Georgetown University Medical Center, Washington, DC
| | | | | | | |
Collapse
|
38
|
Geraldo LP, Semmler R, Gonçalez OL, Mesa J, Arruda-Neto JDT, Garcia F, Rodriguez O. Photofission Cross Sections for237Np in the Energy Interval from 5.27 to 10.83 MeV. NUCL SCI ENG 2017. [DOI: 10.13182/nse00-a2164] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- L. P. Geraldo
- Instituto de Pesquisas Científicas-IPEC/UNISANTOS, Rua Piauí 58, 11065-420 Santos (SP), Brazil
| | - R. Semmler
- Instituto de Pesquisas Energéticas e Nucleares (IPEN-CNEN/SP), Divisão de Física Nuclear C.P. 11049, Pinheiros, 05422-970 São Paulo (SP), Brazil
| | - O. L. Gonçalez
- Instituto de Estudos Avançados/CTA, C.P. 6044, 12231-970 São José dos Campos (SP), Brazil
| | - J. Mesa
- Universidade de São Paulo, Laboratório do Acelerador Linear, Instituto de Física C.P. 66318, 05389-970 São Paulo (SP), Brazil
| | - J. D. T. Arruda-Neto
- Universidade de São Paulo, Laboratório do Acelerador Linear, Instituto de Física C.P. 66318, 05389-970 São Paulo (SP), Brazil
| | - F. Garcia
- Universidade de São Paulo, Laboratório do Acelerador Linear, Instituto de Física C.P. 66318, 05389-970 São Paulo (SP), Brazil
| | - O. Rodriguez
- Universidade de São Paulo, Laboratório do Acelerador Linear, Instituto de Física C.P. 66318, 05389-970 São Paulo (SP), Brazil
| |
Collapse
|
39
|
Twardowski P, Pal S, Stein C, Frankel P, Chen H, Moore T, Harwood D, Prajapati M, Junqueira M, Chung S, Rahmanuddin S, Burns K, Rodriguez O, Woo D, Tryon P, Park J. F18 NaF PET/CT and whole body MRI for the detection of metastases in patients with biochemical recurrence of prostate cancer. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw372.47] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
40
|
Valenson W, Valmonte F, Rodriguez O, Medina E, Lowrey M, Lew S, DeLeon A, Armstrong J, Rippberger E, Maddock L, Nguyen H. Perceived Barriers to Physical Activity in Patients at High Risk for COPD Exacerbations. Chest 2016. [DOI: 10.1016/j.chest.2016.08.992] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
41
|
Abstract
Despite the impressive advances in electron beam irradiation, the technology is not ready for application to all types of fresh and/or minimally processed fruits and vegetables. The relationships between food product quality (nutrients, colour and texture) and irradiation dose are still needed. Cantaloupes ( Cucumis melo, L.) have become a product of interest due to the recent food-borne illness outbreaks related to their consumption in the United States and other countries. The main goal of this study was to verify whether treatment of cantaloupes using electron beam technology has any detrimental effects on the product quality. Whole and fresh-cut packaged cantaloupes were irradiated using a linear electron beam accelerator with the single beam (10MeV) fixture. Samples were stored at 10°C for zero, 4, 8 and 12 days along with control (non-irradiated) samples and tested for colour, texture (firmness), size (density), sugars and carotene content to determine the effect of irradiation dose level (1.0, 1.5 and 3.1kGy). Results indicated that irradiation of cantaloupes, as whole fruits with dose up to 1.0kGy, caused no significant changes on the fruit’s physical and nutritional quality attributes. Irradiating at higher doses had an undesirable effect on product quality. The fresh-cut packaged cantaloupe may be irradiated up to 1.5kGy without worsening the product quality attributes. In both cases, carotene content slightly increased as irradiation dose increased. In general, samples irradiated with dose levels between 1.0-1.5kGy had better quality attributes than the non-irradiated samples.
Collapse
Affiliation(s)
- E. Castell-Perez
- Department of Biological and Agricultural Engineering, Texas A&M University, College Station, Texas, 77843-2117 USA,
| | - M. Moreno
- Department of Biological and Agricultural Engineering, Texas A&M University, College Station, Texas, 77843-2117 USA
| | - O. Rodriguez
- Department of Biological and Agricultural Engineering, Texas A&M University, College Station, Texas, 77843-2117 USA
| | - R. G. Moreira
- Department of Biological and Agricultural Engineering, Texas A&M University, College Station, Texas, 77843-2117 USA
| |
Collapse
|
42
|
Brosch R, Butterworth S, Brandl S, Rodriguez O, Benner D. Dietitian Acceptance and Effectiveness of a Motivational Interviewing Approach to Dialysis Patient Engagement. J Acad Nutr Diet 2016. [DOI: 10.1016/j.jand.2016.06.161] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
43
|
Alguacil FJ, Lopez FA, Rodriguez O, Martinez-Ramirez S, Garcia-Diaz I. Sorption of indium (III) onto carbon nanotubes. Ecotoxicol Environ Saf 2016; 130:81-6. [PMID: 27085001 DOI: 10.1016/j.ecoenv.2016.04.008] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/20/2015] [Revised: 04/04/2016] [Accepted: 04/07/2016] [Indexed: 05/26/2023]
Abstract
Indium has numerous applications in different industrial sectors and is not an abundant element. Therefore appropriate technology to recover this element from various process wastes is needed. This research reports high adsorption capacity of multiwalled carbon nanotubes (MWCNT) for In(III). The effects of pH, kinetics, isotherms and adsorption mechanism of MWCNT on In(III) adsorption were investigated and discussed in detail. The pH increases improves the adsorption capacity for In(III). The Langmuir adsorption model is the best fit with the experimental data. For the kinetic study, the adsorption onto MWCNT could be fitted to pseudo second-order. The adsorption of indium(III) can be described to a mechanism which consists of a film diffusion controlled process. Metal desorption can be achieved with acidic solutions.
Collapse
Affiliation(s)
- F J Alguacil
- Centro Nacional de Investigaciones Metalúrgicas (CSIC), Ciudad Universitaria, Avda. Gregorio del Amo 8, 28040 Madrid, Spain.
| | - F A Lopez
- Centro Nacional de Investigaciones Metalúrgicas (CSIC), Ciudad Universitaria, Avda. Gregorio del Amo 8, 28040 Madrid, Spain
| | - O Rodriguez
- Centro Nacional de Investigaciones Metalúrgicas (CSIC), Ciudad Universitaria, Avda. Gregorio del Amo 8, 28040 Madrid, Spain
| | - S Martinez-Ramirez
- Instituto de Estructura de la Materia (IEM-CSIC), C/Serrano, 121, 28006 Madrid, Spain
| | - I Garcia-Diaz
- Centro Nacional de Investigaciones Metalúrgicas (CSIC), Ciudad Universitaria, Avda. Gregorio del Amo 8, 28040 Madrid, Spain
| |
Collapse
|
44
|
Tilan JU, Hong SH, Galli S, Acree R, Connors K, Horton M, Mahajan A, Wietlisbach L, Lee YC, Rodriguez O, Albanese C, Kitlinska J. Abstract 2478: Tumor hypoxia promotes Ewing sarcoma metastases in a mouse xenograft model. Cancer Res 2016. [DOI: 10.1158/1538-7445.am2016-2478] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Ewing sarcoma (ES) is a pediatric tumor induced by EWS-ETS fusion proteins, most often EWS-FLI1. While the presence of metastases is the single most powerful adverse prognostic factor for ES patients, the mechanisms underlying their development remain unclear. Tumor hypoxia is one of the few factors implicated in ES progression. In ES patients, the presence of nonperfused areas within tumor tissue was associated with poor prognosis. In vitro, hypoxia increases invasiveness of ES cells and triggers expression of pro-metastatic genes via changes in transcriptional activity of the EWS-FLI1 gene. However, despite this line of evidence, no direct proof for this hypoxia-induced ES progression and spread has been provided. Moreover, the mechanisms by which hypoxia could exert such effects are unknown. To fill this gap, we created an in vivo model of hypoxia in ES and tested its effect on tumor metastasis. SK-ES1 ES cells were injected into gastrocnemius muscles of SCID/beige mice. Once the tumors reached a volume of 250mm3, they were either excised (control) or subjected to femoral artery ligation (FAL) for 72h prior to excision, inducing ischemia of the lower hindlimb, thus creating tumor hypoxia. Then, the mice were monitored for metastases. The extent of the metastatic disease was assessed and compared between experimental groups based on periodic MRI, necropsy and histopathology findings. FAL resulted in profound tumor hypoxia, as evidenced by inhibition of primary tumor growth, severe tissue necrosis and positive staining for a hypoxyprobe, pimonidazole. However, despite the impaired growth of primary tumors, xenografts subjected to FAL were more metastatic. The involvement of hypoxic cells in metastases was evidenced by the accumulation of pimonidazole-positive cells (hypoxic at the time of FAL) in areas of tissue invasion and intravasation. Consequently, mice bearing FAL-treated tumors exhibited a decreased latency of metastases formation and an increase in their number from an average of 0.9 to 2.3 metastases per mouse in control and FAL groups, respectively. We also observed a change in the pattern of metastases, as FAL-treated tumors metastasized more often to distant organs (average of 0.3 organ metastases per mouse in control and 1.3 in FAL group). The hypoxia-induced metastases were most often observed in adrenal gland and spine (50% and 42% of mice in FAL group, respectively), while no such metastases were observed in the control group. Moreover, 100% of FAL-treated mice had signs of bone marrow invasion, while no tumor cells were detectable in bone marrow of control mice. This data provides the first-ever direct evidence for tumor hypoxia as a driver of ES metastases. Moreover, our model of tumor hypoxia in vivo provides an excellent opportunity to identify hypoxia-induced pathways involved in ES metastatic progression that subsequently may become novel therapeutic targets for this disease.
Citation Format: Jason U. Tilan, Sung-Hyeok Hong, Susana Galli, Rachel Acree, Katherine Connors, Meredith Horton, Akanksha Mahajan, Larissa Wietlisbach, Yi-Chien Lee, Olga Rodriguez, Christopher Albanese, Joanna Kitlinska. Tumor hypoxia promotes Ewing sarcoma metastases in a mouse xenograft model. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 2478.
Collapse
Affiliation(s)
| | | | - Susana Galli
- Georgetown University Medical Center, Washington, DC
| | - Rachel Acree
- Georgetown University Medical Center, Washington, DC
| | | | | | | | | | - Yi-Chien Lee
- Georgetown University Medical Center, Washington, DC
| | | | | | | |
Collapse
|
45
|
Serra V, Palafox M, Herrera MT, Rivas MA, Guzmán M, Rodriguez O, Grueso J, Bellet M, Oliveira M, Saura C, di Tomaso E, Camponigro G, Turner NC, Cortés J, Baselga J. Abstract 2825: Identification of CDK4/6-response biomarkers using estrogen receptor-positive breast cancer patient-derived xenografts (PDX). Cancer Res 2016. [DOI: 10.1158/1538-7445.am2016-2825] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Endocrine resistance is a clinical challenge for the treatment of estrogen receptor positive (ER+) breast cancer (BC). CDK4/6 blockade in combination with endocrine therapy has shown clinical activity in metastatic ER+ BC refractory to anti-hormonal treatment. However, there is a need for biomarkers that can predict the response to this treatment and improve patient stratification. We aimed to address this issue using xenograft models established from samples of ER+ BC patients.
Six ER+ PDXs were treated with continuous doses of a CDK4/6 inhibitor (LEE011, 75mg/kg, 6IW) and a PI3K-alpha inhibitor (BYL719, 35mg/kg, 6IW) as single agents and in combination, and intrinsic sensitivity to these agents was evaluated. The models were then genomically characterized using a capture-based sequencing panel and by digital PCR.
One PDX model was intrinsically sensitive to single-agent CDK4/6 inhibition and experienced tumor regression, but all individual tumors eventually escaped therapy after 50 days of treatment. This particular model harbored an ESR1-mutation and concomitant losses of CDKN2A/B. At relapse, we identified the acquisition of an RB1 frameshift mutation. Interestingly, upfront combined treatment with a PI3K-alpha inhibitor delayed the onset of tumor progression. Two out of the remaining five CDK4/6-resistant PDXs harbored either a frameshift mutation in RB1 (plus loss of heterozygosity) or had low pRb protein expression. Two other resistant models harbored CCND1 and MYC amplifications. The remaining one harbored a TSC1 loss. In all the CDK4/6-resistant PDX, however, the combination of CDK4/6 and PI3K-alpha inhibition resulted in tumor regression.
From our results, we conclude that loss of G1-cell cycle checkpoint control, such as mutation/loss of RB1 and CCND1-amplification, is associated with lack of response to CDK4/6 blockade in ER+ BC PDX. The addition of a PI3K-alpha inhibitor results in improvement of disease control in all experimental models tested.
Citation Format: Violeta Serra, Marta Palafox, Maria-Teresa Herrera, Martin A Rivas, Marta Guzmán, Olga Rodriguez, Judit Grueso, Meritxell Bellet, Mafalda Oliveira, Cristina Saura, Emmanuelle di Tomaso, Giordi Camponigro, Nicholas C. Turner, Javier Cortés, José Baselga. Identification of CDK4/6-response biomarkers using estrogen receptor-positive breast cancer patient-derived xenografts (PDX). [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 2825.
Collapse
Affiliation(s)
| | | | | | | | - Marta Guzmán
- 1Vall d’Hebron Inst. of Oncology, Barcelona, Spain
| | | | - Judit Grueso
- 1Vall d’Hebron Inst. of Oncology, Barcelona, Spain
| | | | | | | | | | | | | | | | - José Baselga
- 4Memorial Sloan Kettering Cancer Center, New York, NY
| |
Collapse
|
46
|
Naeem A, Yenugonda V, Rodriguez O, Avantaggiati M, Rood B, Karam S, Albanese C. Mechanisms of p53-mediated chemosensitivity of VMY on medulloblastoma cells. Eur J Cancer 2016. [DOI: 10.1016/s0959-8049(16)61315-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
47
|
Rodriguez O, Schaefer ML, Wester B, Lee YC, Boggs N, Conner HA, Merkle AC, Fricke ST, Albanese C, Koliatsos VE. Manganese-Enhanced Magnetic Resonance Imaging as a Diagnostic and Dispositional Tool after Mild-Moderate Blast Traumatic Brain Injury. J Neurotrauma 2016; 33:662-71. [PMID: 26414591 PMCID: PMC4827293 DOI: 10.1089/neu.2015.4002] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Traumatic brain injury (TBI) caused by explosive munitions, known as blast TBI, is the signature injury in recent military conflicts in Iraq and Afghanistan. Diagnostic evaluation of TBI, including blast TBI, is based on clinical history, symptoms, and neuropsychological testing, all of which can result in misdiagnosis or underdiagnosis of this condition, particularly in the case of TBI of mild-to-moderate severity. Prognosis is currently determined by TBI severity, recurrence, and type of pathology, and also may be influenced by promptness of clinical intervention when more effective treatments become available. An important task is prevention of repetitive TBI, particularly when the patient is still symptomatic. For these reasons, the establishment of quantitative biological markers can serve to improve diagnosis and preventative or therapeutic management. In this study, we used a shock-tube model of blast TBI to determine whether manganese-enhanced magnetic resonance imaging (MEMRI) can serve as a tool to accurately and quantitatively diagnose mild-to-moderate blast TBI. Mice were subjected to a 30 psig blast and administered a single dose of MnCl2 intraperitoneally. Longitudinal T1-magnetic resonance imaging (MRI) performed at 6, 24, 48, and 72 h and at 14 and 28 days revealed a marked signal enhancement in the brain of mice exposed to blast, compared with sham controls, at nearly all time-points. Interestingly, when mice were protected with a polycarbonate body shield during blast exposure, the marked increase in contrast was prevented. We conclude that manganese uptake can serve as a quantitative biomarker for TBI and that MEMRI is a minimally-invasive quantitative approach that can aid in the accurate diagnosis and management of blast TBI. In addition, the prevention of the increased uptake of manganese by body protection strongly suggests that the exposure of an individual to blast risk could benefit from the design of improved body armor.
Collapse
Affiliation(s)
- Olga Rodriguez
- Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC
| | - Michele L. Schaefer
- Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland
| | - Brock Wester
- Research and Exploratory Development Department, Johns Hopkins University, Applied Physics Laboratory, Laurel, Maryland
| | - Yi-Chien Lee
- Department of Oncology, Georgetown University Medical Center, Washington DC
| | - Nathan Boggs
- Research and Exploratory Development Department, Johns Hopkins University, Applied Physics Laboratory, Laurel, Maryland
| | - Howard A. Conner
- Research and Exploratory Development Department, Johns Hopkins University, Applied Physics Laboratory, Laurel, Maryland
| | - Andrew C. Merkle
- Research and Exploratory Development Department, Johns Hopkins University, Applied Physics Laboratory, Laurel, Maryland
| | - Stanley T. Fricke
- Pediatric and Integrative Systems Biology, George Washington University, Washington, DC
| | - Chris Albanese
- Department of Oncology, Georgetown University Medical Center, Washington DC
- Department of Pathology, Georgetown University Medical Center, Washington DC
| | - Vassilis E. Koliatsos
- Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland
- Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland
| |
Collapse
|
48
|
Herrera-Abreu MT, Palafox M, Asghar U, Rivas MA, Cutts RJ, Garcia-Murillas I, Pearson A, Guzman M, Rodriguez O, Grueso J, Bellet M, Cortés J, Elliott R, Pancholi S, Baselga J, Dowsett M, Martin LA, Turner NC, Serra V. Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer. Cancer Res 2016; 76:2301-13. [PMID: 27020857 DOI: 10.1158/0008-5472.can-15-0728] [Citation(s) in RCA: 457] [Impact Index Per Article: 57.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2015] [Accepted: 01/29/2016] [Indexed: 01/02/2023]
Abstract
Small-molecule inhibitors of the CDK4/6 cell-cycle kinases have shown clinical efficacy in estrogen receptor (ER)-positive metastatic breast cancer, although their cytostatic effects are limited by primary and acquired resistance. Here we report that ER-positive breast cancer cells can adapt quickly to CDK4/6 inhibition and evade cytostasis, in part, via noncanonical cyclin D1-CDK2-mediated S-phase entry. This adaptation was prevented by cotreatment with hormone therapies or PI3K inhibitors, which reduced the levels of cyclin D1 (CCND1) and other G1-S cyclins, abolished pRb phosphorylation, and inhibited activation of S-phase transcriptional programs. Combined targeting of both CDK4/6 and PI3K triggered cancer cell apoptosis in vitro and in patient-derived tumor xenograft (PDX) models, resulting in tumor regression and improved disease control. Furthermore, a triple combination of endocrine therapy, CDK4/6, and PI3K inhibition was more effective than paired combinations, provoking rapid tumor regressions in a PDX model. Mechanistic investigations showed that acquired resistance to CDK4/6 inhibition resulted from bypass of cyclin D1-CDK4/6 dependency through selection of CCNE1 amplification or RB1 loss. Notably, although PI3K inhibitors could prevent resistance to CDK4/6 inhibitors, they failed to resensitize cells once resistance had been acquired. However, we found that cells acquiring resistance to CDK4/6 inhibitors due to CCNE1 amplification could be resensitized by targeting CDK2. Overall, our results illustrate convergent mechanisms of early adaptation and acquired resistance to CDK4/6 inhibitors that enable alternate means of S-phase entry, highlighting strategies to prevent the acquisition of therapeutic resistance to these agents. Cancer Res; 76(8); 2301-13. ©2016 AACR.
Collapse
Affiliation(s)
| | - Marta Palafox
- Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain
| | - Uzma Asghar
- The Breast Cancer Now Research Centre, Institute of Cancer Research, London, United Kingdom
| | - Martín A Rivas
- Weill Cornell Medicine, Cornell University, New York, New York
| | - Rosalind J Cutts
- The Breast Cancer Now Research Centre, Institute of Cancer Research, London, United Kingdom
| | - Isaac Garcia-Murillas
- The Breast Cancer Now Research Centre, Institute of Cancer Research, London, United Kingdom
| | - Alex Pearson
- The Breast Cancer Now Research Centre, Institute of Cancer Research, London, United Kingdom
| | - Marta Guzman
- Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain
| | - Olga Rodriguez
- Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain
| | - Judit Grueso
- Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain
| | | | | | - Richard Elliott
- The Breast Cancer Now Research Centre, Institute of Cancer Research, London, United Kingdom
| | - Sunil Pancholi
- The Breast Cancer Now Research Centre, Institute of Cancer Research, London, United Kingdom
| | - José Baselga
- Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York
| | - Mitch Dowsett
- The Breast Cancer Now Research Centre, Institute of Cancer Research, London, United Kingdom. Academic Department of Biochemistry, Royal Marsden Hospital, London, United Kingdom
| | - Lesley-Ann Martin
- The Breast Cancer Now Research Centre, Institute of Cancer Research, London, United Kingdom
| | - Nicholas C Turner
- The Breast Cancer Now Research Centre, Institute of Cancer Research, London, United Kingdom. Breast Unit, Royal Marsden Hospital, London, United Kingdom.
| | - Violeta Serra
- Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
| |
Collapse
|
49
|
Bhatia S, Baig NA, Timofeeva O, Pasquale EB, Hirsch K, MacDonald TJ, Dritschilo A, Lee YC, Henkemeyer M, Rood B, Jung M, Wang XJ, Kool M, Rodriguez O, Albanese C, Karam SD. Knockdown of EphB1 receptor decreases medulloblastoma cell growth and migration and increases cellular radiosensitization. Oncotarget 2016; 6:8929-46. [PMID: 25879388 PMCID: PMC4496193 DOI: 10.18632/oncotarget.3369] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2014] [Accepted: 02/11/2015] [Indexed: 02/03/2023] Open
Abstract
The expression of members of the Eph family of receptor tyrosine kinases and their ephrin ligands is frequently dysregulated in medulloblastomas. We assessed the expression and functional role of EphB1 in medulloblastoma cell lines and engineered mouse models. mRNA and protein expression profiling showed expression of EphB1 receptor in the human medulloblastoma cell lines DAOY and UW228. EphB1 downregulation reduced cell growth and viability, decreased the expression of important cell cycle regulators, and increased the percentage of cells in G1 phase of the cell cycle. It also modulated the expression of proliferation, and cell survival markers. In addition, EphB1 knockdown in DAOY cells resulted in significant decrease in migration, which correlated with decreased β1-integrin expression and levels of phosphorylated Src. Furthermore, EphB1 knockdown enhanced cellular radiosensitization of medulloblastoma cells in culture and in a genetically engineered mouse medulloblastoma model. Using genetically engineered mouse models, we established that genetic loss of EphB1 resulted in a significant delay in tumor recurrence following irradiation compared to EphB1-expressing control tumors. Taken together, our findings establish that EphB1 plays a key role in medulloblastoma cell growth, viability, migration, and radiation sensitivity, making EphB1 a promising therapeutic target.
Collapse
Affiliation(s)
- Shilpa Bhatia
- Department of Radiation Oncology, University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, USA
| | - Nimrah A Baig
- Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA
| | - Olga Timofeeva
- Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA
| | | | - Kellen Hirsch
- Department of Radiation Oncology, University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, USA
| | - Tobey J MacDonald
- Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA
| | - Anatoly Dritschilo
- Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA.,Georgetown University Hospital, Washington, DC, USA
| | - Yi Chien Lee
- Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA
| | - Mark Henkemeyer
- Department of Developmental Biology, University of Texas Southwestern Medical Center, Dallas, TX, USA
| | - Brian Rood
- Children's National Medical Center, Washington DC, USA
| | - Mira Jung
- Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA
| | - Xiao-Jing Wang
- Department of Pathology, University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, USA
| | - Marcel Kool
- Division of Pediatric Neurooncology, German Cancer Research Center DKFZ, Heidelberg, Germany
| | - Olga Rodriguez
- Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA
| | - Chris Albanese
- Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA.,Department of Pathology, Georgetown University School of Medicine, Washington, DC, USA
| | - Sana D Karam
- Department of Radiation Oncology, University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, USA.,Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA
| |
Collapse
|
50
|
Roux D, Meyer G, Cymbalista F, Bouaziz JD, Falgarone G, Tesniere A, Gervais J, Cariou A, Peffault de Latour R, Marat M, Moenaert E, Guebli T, Rodriguez O, Lefort A, Dreyfuss D, Hajage D, Ricard JD. [Computerized ranking test in three French universities: Staff experience and students' feedback]. Rev Med Interne 2016; 37:166-72. [PMID: 26827272 DOI: 10.1016/j.revmed.2015.12.026] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2015] [Revised: 11/26/2015] [Accepted: 12/29/2015] [Indexed: 10/22/2022]
Abstract
BACKGROUND The year 2016 will be pivotal for the evaluation of French medical students with the introduction of the first computerized National Ranking Test (ECNi). The SIDES, online electronic system for medical student evaluation, was created for this purpose. All the universities have already organized faculty exams but few a joint computerized ranking test at several universities simultaneously. We report our experience on the organization of a mock ECNi by universities Paris Descartes, Paris Diderot and Paris 13. METHODS Docimological, administrative and technical working groups were created to organize this ECNi. Students in their fifth year of medical studies, who will be the first students to sit for the official ECNi in 2016, were invited to attend this mock exam that represented more than 50% of what will be proposed in 2016. A final electronic questionnaire allowed a docimological and organizational evaluation by students. An analysis of ratings and rankings and their distribution on a 1000-point scale were performed. RESULTS Sixty-four percent of enrolled students (i.e., 654) attended the three half-day exams. No difference in total score and ranking between the three universities was observed. Students' feedback was extremely positive. Normalized over 1000 points, 99% of students were scored on 300 points only. Progressive clinical cases were the most discriminating test. CONCLUSION The organization of a mock ECNi involving multiple universities was a docimological and technical success but required an important administrative, technical and teaching investment.
Collapse
Affiliation(s)
- D Roux
- Université Paris Diderot, Sorbonne Paris Cité, 75205 Paris, France; Service de réanimation médicochirurgicale, hôpital Louis-Mourier, AP-HP, 178, rue des Renouillers, 92700 Colombes, France.
| | - G Meyer
- Université Paris Descartes, Sorbonne Paris Cité, 75006 Paris, France; Service de pneumologie, hôpital européen Georges-Pompidou, AP-HP, 75015 Paris, France
| | - F Cymbalista
- Université Paris 13, Sorbonne Paris Cité, 93000 Bobigny, France; Service d'hématologie biologique, hôpital Avicenne, AP-HP, 93000 Bobigny, France
| | - J-D Bouaziz
- Université Paris Diderot, Sorbonne Paris Cité, 75205 Paris, France; Service de dermatologie, hôpital Saint-Louis, AP-HP, 75010 Paris, France
| | - G Falgarone
- Université Paris 13, Sorbonne Paris Cité, 93000 Bobigny, France; Service de rhumatologie, hôpital Avicenne, AP-HP, 93000 Bobigny, France
| | - A Tesniere
- Université Paris Descartes, Sorbonne Paris Cité, 75006 Paris, France; Service de réanimation chirurgicale, hôpital Cochin, AP-HP, 74014 Paris, France
| | - J Gervais
- Université Paris Diderot, Sorbonne Paris Cité, 75205 Paris, France
| | - A Cariou
- Université Paris Descartes, Sorbonne Paris Cité, 75006 Paris, France; Service de réanimation médicale, hôpital Cochin, AP-HP, 74014 Paris, France
| | - R Peffault de Latour
- Université Paris Diderot, Sorbonne Paris Cité, 75205 Paris, France; Service d'hématologie greffe, hôpital Saint-Louis, AP-HP, 75010 Paris, France
| | - M Marat
- Université Paris Descartes, Sorbonne Paris Cité, 75006 Paris, France
| | - E Moenaert
- Université Paris Diderot, Sorbonne Paris Cité, 75205 Paris, France
| | - T Guebli
- Université Paris 13, Sorbonne Paris Cité, 93000 Bobigny, France
| | - O Rodriguez
- Université Paris Descartes, Sorbonne Paris Cité, 75006 Paris, France
| | - A Lefort
- Université Paris Diderot, Sorbonne Paris Cité, 75205 Paris, France; Service de médecine interne, hôpital Beaujon, AP-HP, 92110 Clichy, France
| | - D Dreyfuss
- Université Paris Diderot, Sorbonne Paris Cité, 75205 Paris, France; Service de réanimation médicochirurgicale, hôpital Louis-Mourier, AP-HP, 178, rue des Renouillers, 92700 Colombes, France
| | - D Hajage
- Université Paris Diderot, Sorbonne Paris Cité, 75205 Paris, France; Département d'épidémiologie et de recherche clinique, hôpital Louis-Mourier, AP-HP, 92700 Colombes, France
| | - J-D Ricard
- Université Paris Diderot, Sorbonne Paris Cité, 75205 Paris, France; Service de réanimation médicochirurgicale, hôpital Louis-Mourier, AP-HP, 178, rue des Renouillers, 92700 Colombes, France
| |
Collapse
|